@article {pmid38935987,
year = {2024},
author = {Weis, KL and Trout, KK and Cimiotti, JP and Deupree, JP and Killion, C and Peter, E and Polivka, B and Shieh, C},
title = {The nurse's role in a patient-centered approach for reducing COVID-19 vaccine hesitancy during pregnancy: An American Academy of Nursing consensus paper.},
journal = {Nursing outlook},
volume = {72},
number = {5},
pages = {102196},
doi = {10.1016/j.outlook.2024.102196},
pmid = {38935987},
issn = {1528-3968},
mesh = {Humans ; Female ; Pregnancy ; *COVID-19 Vaccines/administration & dosage ; *Patient-Centered Care ; *COVID-19/prevention & control ; *Nurse's Role ; *Vaccination Hesitancy/psychology ; Adult ; United States ; Pregnancy Complications, Infectious/prevention & control ; },
abstract = {The evidence shows that COVID-19 vaccines can reduce the risks of poor pregnancy outcomes. Yet, reluctance to vaccinate remains high in pregnant populations. In this paper, we take a precision health and patient-centered approach to vaccine hesitancy. We adopted the society-to-cells vaccine hesitancy framework to identify society, community, family, individual, and physiologic factors contributing to COVID-19 vaccine hesitancy in pregnancy. Nurses are particularly well-suited to impact the factors associated with vaccine hesitancy. Because of their proximity to the patient, nurses are positioned to provide individualized, timely health information, and clinical guidelines to assist patients with decision-making related to vaccinations. Recommendations are provided to bolster nurses' engagement in precision health and patient-centered models of care to mitigate COVID-19 vaccine hesitancy in pregnancy.},
}

Humans
Female
Pregnancy
*COVID-19 Vaccines/administration & dosage
*Patient-Centered Care
*COVID-19/prevention & control
*Nurse's Role
*Vaccination Hesitancy/psychology
Adult
United States
Pregnancy Complications, Infectious/prevention & control

@article {pmid38823451,
year = {2024},
author = {Meijer, SE and Paran, Y and Belkin, A and Brosh-Nissimov, T},
title = {'Persistent COVID-19 in immunocompromised patients - Israeli society of infectious diseases consensus statement on diagnosis and management': author's response.},
journal = {Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
volume = {30},
number = {9},
pages = {1211-1212},
doi = {10.1016/j.cmi.2024.05.022},
pmid = {38823451},
issn = {1469-0691},
mesh = {Humans ; *COVID-19/diagnosis/immunology ; *Immunocompromised Host ; *SARS-CoV-2/immunology ; Israel/epidemiology ; },
}

Humans
*COVID-19/diagnosis/immunology
*Immunocompromised Host
*SARS-CoV-2/immunology
Israel/epidemiology

@article {pmid38386716,
year = {2024},
author = {Song, P and Adeloye, D and Acharya, Y and Bojude, DA and Ali, S and Alibudbud, R and Bastien, S and Becerra-Posada, F and Berecki, M and Bodomo, A and Borrescio-Higa, F and Buchtova, M and Campbell, H and Chan, KY and Cheema, S and Chopra, M and Cipta, DA and Castro, LD and Ganasegeran, K and Gebre, T and Glasnović, A and Graham, CJ and Igwesi-Chidobe, C and Iversen, PO and Jadoon, B and Lanza, G and Macdonald, C and Park, C and Islam, MM and Mshelia, S and Nair, H and Ng, ZX and Htay, MNN and Akinyemi, KO and Parisi, M and Patel, S and Peprah, P and Polasek, O and Riha, R and Rotarou, ES and Sacks, E and Sharov, K and Stankov, S and Supriyatiningsih, W and Sutan, R and Tomlinson, M and Tsai, AC and Tsimpida, D and Vento, S and Glasnović, JV and Vokey, LBV and Wang, L and Wazny, K and Xu, J and Yoshida, S and Zhang, Y and Cao, J and Zhu, Y and Sheikh, A and Rudan, I and , },
title = {Setting research priorities for global pandemic preparedness: An international consensus and comparison with ChatGPT's output.},
journal = {Journal of global health},
volume = {14},
number = {},
pages = {04054},
pmid = {38386716},
issn = {2047-2986},
support = {001/WHO_/World Health Organization/International ; },
mesh = {Child ; Humans ; *Pandemic Preparedness ; Research Design ; *COVID-19/epidemiology/prevention & control ; Child Health ; },
abstract = {BACKGROUND: In this priority-setting exercise, we sought to identify leading research priorities needed for strengthening future pandemic preparedness and response across countries.

METHODS: The International Society of Global Health (ISoGH) used the Child Health and Nutrition Research Initiative (CHNRI) method to identify research priorities for future pandemic preparedness. Eighty experts in global health, translational and clinical research identified 163 research ideas, of which 42 experts then scored based on five pre-defined criteria. We calculated intermediate criterion-specific scores and overall research priority scores from the mean of individual scores for each research idea. We used a bootstrap (n = 1000) to compute the 95% confidence intervals.

RESULTS: Key priorities included strengthening health systems, rapid vaccine and treatment production, improving international cooperation, and enhancing surveillance efficiency. Other priorities included learning from the coronavirus disease 2019 (COVID-19) pandemic, managing supply chains, identifying planning gaps, and promoting equitable interventions. We compared this CHNRI-based outcome with the 14 research priorities generated and ranked by ChatGPT, encountering both striking similarities and clear differences.

CONCLUSIONS: Priority setting processes based on human crowdsourcing - such as the CHNRI method - and the output provided by ChatGPT are both valuable, as they complement and strengthen each other. The priorities identified by ChatGPT were more grounded in theory, while those identified by CHNRI were guided by recent practical experiences. Addressing these priorities, along with improvements in health planning, equitable community-based interventions, and the capacity of primary health care, is vital for better pandemic preparedness and response in many settings.},
}

Child
Humans
*Pandemic Preparedness
Research Design
*COVID-19/epidemiology/prevention & control
Child Health

@article {pmid38328958,
year = {2024},
author = {Campos Del Portillo, R and Palma Milla, S and Matía Martín, P and Loria-Kohen, V and Martínez Olmos, MÁ and Mories Álvarez, MT and Castro Alija, MJ and Martín Palmero, MÁ and Carrillo Lozano, E and Valero-Pérez, M and Campos Del Portillo, I and Sirvent Segovia, AE and Plaza Blázquez, P and de la Cruz López, DM and Pita Gutiérrez, F},
title = {[A consensus report by the Working Group on Eating Disorders of Sociedad Española de Nutrición Clínica y Metabolismo (GTTCA-SENPE). Evaluation, medical and nutritional management of anorexia nervosa. Update 2023].},
journal = {Nutricion hospitalaria},
volume = {41},
number = {Spec No1},
pages = {1-60},
doi = {10.20960/nh.05175},
pmid = {38328958},
issn = {1699-5198},
mesh = {Adult ; Humans ; Child ; *Anorexia Nervosa/complications/therapy/psychology ; *Transition to Adult Care ; *Feeding and Eating Disorders ; *Malnutrition/therapy ; },
abstract = {Anorexia nervosa (AN) is a multifactorial disorder. A possible role of the social network and the gut microbiota in pathogenesis has been added. Exogenous shocks such as the COVID19 pandemic have had a negative impact on patients with AN. The potential medical and nutritional impact of malnutrition and/or compensatory behaviors gives rise to a complex disease with a wide range of severity, the management of which requires a multidisciplinary team with a high level of subject matter expertise. Coordination between levels of care is necessary as well as understanding how to transition the patient from pediatric to adult care is essential. A proper clinical evaluation can detect possible complications, as well as establish the organic risk of the patient. This allows caregivers to tailor the medical-nutritional treatment for each patient. Reestablishing adequate nutritional behaviors is a fundamental pillar of treatment in AN. The design of a personalized nutritional treatment and education program is necessary for this purpose. Depending on the clinical severity, artificial nutrition may be necessary. Although the decision regarding the level of care necessary at diagnosis or during follow-up depends on a number of factors (awareness of the disease, medical stability, complications, suicidal risk, outpatient treatment failure, psychosocial context, etc.), outpatient treatment is the most frequent and most preferred choice. However, more intensive care (total or partial hospitalization) may be necessary in certain cases. In severely malnourished patients, the appearance of refeeding syndrome should be prevented during renourishment. The presence of AN in certain situations (pregnancy, vegetarianism, type 1 diabetes mellitus) requires specific care. Physical activity in these patients must also be addressed correctly.},
}

Adult
Humans
Child
*Anorexia Nervosa/complications/therapy/psychology
*Transition to Adult Care
*Feeding and Eating Disorders
*Malnutrition/therapy

@article {pmid37743239,
year = {2023},
author = {Anderson, MA and Bennett, R and Badoux, X and Best, G and Chia, N and Cochrane, T and Cull, G and Crassini, K and Harrup, R and Jackson, S and Kuss, B and Lasica, M and Lew, TE and Marlton, P and Opat, S and Palfreyman, E and Polizzotto, MN and Ratnasingam, S and Seymour, JF and Soosapilla, A and Talaulikar, D and Tam, CS and Weinkove, R and Wight, J and Mulligan, SP},
title = {Chronic lymphocytic leukaemia Australasian consensus practice statement.},
journal = {Internal medicine journal},
volume = {53},
number = {9},
pages = {1678-1691},
doi = {10.1111/imj.16207},
pmid = {37743239},
issn = {1445-5994},
mesh = {Humans ; *Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/genetics/therapy ; *COVID-19 ; SARS-CoV-2 ; *Hematologic Neoplasms ; },
abstract = {Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic and management algorithms have occurred within the last decade. The availability of next-generation sequencing and measurable residual disease assessment by flow cytometry allow for advanced prognostication and response assessments. Novel therapies, including inhibitors of Bruton's tyrosine kinase (BTKi) and B-cell lymphoma 2 (BCL2) inhibitors, have transformed the treatment landscape for both treatment-naïve and relapsed/refractory disease, particularly for patients with high-risk genetic aberrations. Recommendations regarding appropriate supportive management continue to evolve, and special considerations are required for patients with CLL with respect to the global SARS-CoV-2 pandemic. The unique funding and treatment environments in Australasia highlight the need for specific local guidance with respect to the investigation and management of CLL. This consensus practice statement was developed by a broadly representative group of ANZ experts in CLL with endorsement by peak haematology bodies, with a view to providing this standardised guidance.},
}

Humans
*Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/genetics/therapy
*COVID-19
SARS-CoV-2
*Hematologic Neoplasms

@article {pmid37507424,
year = {2023},
author = {Terpos, E and Musto, P and Engelhardt, M and Ntanasis-Stathopoulos, I and Sonneveld, P and Ludwig, H},
title = {Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensus.},
journal = {Leukemia},
volume = {37},
number = {9},
pages = {1939-1940},
pmid = {37507424},
issn = {1476-5551},
mesh = {Humans ; *COVID-19 ; *Multiple Myeloma/therapy ; COVID-19 Serotherapy ; SARS-CoV-2 ; },
}

Humans
*COVID-19
*Multiple Myeloma/therapy
COVID-19 Serotherapy
SARS-CoV-2

@article {pmid37487775,
year = {2023},
author = {García, FJÁ and Tejada, AMG and Heras, IG and de Arce, AI and Llop, FM and Herreros, FN and Martín, JJP and Marchuet, PS and Rodríguez, JV},
title = {Vaccination schedule for adolescents. Consensus of the AEV, CAV-AEP and SEMA.},
journal = {Anales de pediatria},
volume = {99},
number = {2},
pages = {122-128},
doi = {10.1016/j.anpede.2023.07.004},
pmid = {37487775},
issn = {2341-2879},
mesh = {Child ; Humans ; Adolescent ; *Meningococcal Vaccines ; *Adolescent Medicine ; Immunization Schedule ; *Hepatitis A ; *Meningococcal Infections ; *Whooping Cough ; *COVID-19 ; SARS-CoV-2 ; Vaccination ; },
abstract = {We present the consensus document on the immunization schedule for adolescents developed by 3 scientific societies: the Spanish Association of Pediatrics (AEP), through its Advisory Committee on Vaccines (CAV-AEP), the Spanish Society of Adolescent Medicine (SEMA) and the Spanish Association of Vaccinology (AEV). There are particularities in infectious disease during adolescence, such as an increased susceptibility to pertussis, poorer outcomes of chickenpox, mumps and hepatitis A, a high incidence of sexually transmitted infections or increased prevalence of meningococcal carriage. The document analyses the schedule for adolescents in the context of vaccination policy overall. It contemplates the vaccines to be included in the immunization schedule for healthy adolescents: against invasive meningococcal disease (tetravalent ACWY and B), against human papillomavirus (which should be gender-neutral), against pertussis, against influenza and against SARS-CoV-2 (in unvaccinated individuals and at-risk groups). It is worth noting that the 4CMenB vaccine appears to confer some protection against gonococcal infection, which would be a considerable added value for adolescents. The vaccination of adolescents belonging to risk groups or travelling abroad also needs to be contemplated, as is the case in any other age group. Vaccination against hepatitis A, which is included in the routine immunization schedule of Catalonia, Ceuta and Melilla from the second year of life, should also be considered a priority in adolescents traveling to endemic areas.},
}

Child
Humans
Adolescent
*Meningococcal Vaccines
*Adolescent Medicine
Immunization Schedule
*Hepatitis A
*Meningococcal Infections
*Whooping Cough
*COVID-19
SARS-CoV-2
Vaccination

@article {pmid37399673,
year = {2023},
author = {Silva, BA and Carnero Contentti, E and Becker, J and Carranza, JI and Correa-Díaz, PE and Galleguillos Goiry, L and Garcea, O and Gracia, F and Hamuy, F and Macías, MA and Navas, C and Nuñez, S and Rojas, JI and Farez, MF and Alonso, R and López, P},
title = {Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs.},
journal = {Multiple sclerosis and related disorders},
volume = {77},
number = {},
pages = {104840},
doi = {10.1016/j.msard.2023.104840},
pmid = {37399673},
issn = {2211-0356},
mesh = {Humans ; *Multiple Sclerosis/complications/drug therapy/diagnosis ; Latin America/epidemiology ; *COVID-19 ; Neurologists ; },
abstract = {INTRODUCTION: The emergence of several therapeutic options in multiple sclerosis (MS), which significantly modify the immune system functioning, has led to the need for the consideration of additional factors, such as risk of infections, in the decision-making process. The aim of these consensus recommendations was to discuss and perform a practical guide to Latin American neurologists on the risk of infections at diagnosis, follow-up and prior to initiation of DMDs.

METHODS: A panel of Latin American neurologists, experts in demyelinating diseases and dedicated to management and care of MS patients, gathered during 2021 and 2022 to make consensus recommendations on the risk of infections in PwMS treated with DMDs in Latin America. The RAND/UCLA methodology was developed to synthesize the scientific evidence and expert opinions on health care topics and was used for reaching a formal agreement.

RESULTS: Recommendations were established based on relevant published evidence and expert opinion, focusing on: 1- baseline infection disease and vaccination status; 2- opportunistic infections; 3- progressive multifocal leukoencephalopathy; 4- genitourinary system infections; 5- respiratory tract infections; 6- digestive system infections, 7-others local infections and 8- COVID-19.

CONCLUSION: The recommendations of this consensus seek to optimize the care, management and treatment of PwMS in Latin America. The standardized evidence-based care of pwMS infections will allow better outcomes.},
}

Humans
*Multiple Sclerosis/complications/drug therapy/diagnosis
Latin America/epidemiology
*COVID-19
Neurologists

@article {pmid37099029,
year = {2023},
author = {Terpos, E and Branagan, AR and García-Sanz, R and Trotman, J and Greenberger, LM and Stephens, DM and Morel, P and Kimby, E and Frustaci, AM and Hatjiharissi, E and San-Miguel, J and Dimopoulos, MA and Treon, SP and Leblond, V},
title = {Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management.},
journal = {Seminars in hematology},
volume = {60},
number = {2},
pages = {107-112},
pmid = {37099029},
issn = {1532-8686},
mesh = {Humans ; *Waldenstrom Macroglobulinemia/drug therapy/prevention & control/diagnosis ; COVID-19 Vaccines ; *COVID-19 ; SARS-CoV-2 ; Antiviral Agents/therapeutic use ; },
abstract = {Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current data on the coronavirus disease-2019 (COVID-19) prophylaxis and management in patients with Waldenstrom's Macroglobulinemia (WM). The key recommendations from IWWM-11 CP5 included the following: Booster vaccines for SARS-CoV-2 should be recommended to all patients with WM. Variant-specific booster vaccines, such as the bivalent vaccine for the ancestral Wuhan strain and the Omicron BA.4.5 strain, are important as novel mutants emerge and become dominant in the community. A temporary interruption in Bruton's Tyrosine Kinase-inhibitor (BTKi) or chemoimmunotherapy before vaccination might be considered. Patients under treatment with rituximab or BTK-inhibitors have lower antibody responses against SARS-CoV-2; thus, they should continue to follow preventive measures, including mask wearing and avoiding crowded places. Patients with WM are candidates for preexposure prophylaxis, if available and relevant to the dominant SARS-CoV-2 strains in a specific area. Oral antivirals should be offered to all symptomatic WM patients with mild to moderate COVID-19 regardless of vaccination, disease status or treatment, as soon as possible after the positive test and within 5 days of COVID-19-related symptom onset. Coadministration of ibrutinib or venetoclax with ritonavir should be avoided. In these patients, remdesivir offers an effective alternative. Patients with asymptomatic or oligosymptomatic COVID-19 should not interrupt treatment with a BTK inhibitor. Infection prophylaxis is essential in patients with WM and include general preventive measures, prophylaxis with antivirals and vaccination against common pathogens including SARS-CoV-2, influenza, and S. pneumoniae.},
}

Humans
*Waldenstrom Macroglobulinemia/drug therapy/prevention & control/diagnosis
COVID-19 Vaccines
*COVID-19
SARS-CoV-2
Antiviral Agents/therapeutic use

@article {pmid36999262,
year = {2023},
author = {Aryana, IS and Setiati, S and Mulyana, R and Dwimartutie, N and Rizka, A and Wijaya, BB and Riviati, N and Rensa, R and Ariestine, DA and Karjono, BJ and Aribowo, E and Watupongoh, HHV and Dibyantari, R and Putra, WGS and Triansyah, F and Istanti, R and Daniella, D},
title = {Indonesian Geriatrics Society Consensus on COVID-19 Management in Older Adults.},
journal = {Acta medica Indonesiana},
volume = {55},
number = {1},
pages = {118-131},
pmid = {36999262},
issn = {2338-2732},
mesh = {Humans ; Aged ; Middle Aged ; *COVID-19/therapy ; SARS-CoV-2 ; Indonesia ; *Geriatrics ; },
abstract = {More than 80% of death cases and 95% of severe COVID-19 occur in patients aged over 60 years. Atypical clinical manifestations with high morbidity and mortality further emphasize the importance of COVID-19 management in older adults. Some older patients may appear asymptomatic while other may present with acute respiratory distress syndrome and multi organ failure. Fever, higher respiratory rate and crackles may present. The most common chest x-ray finding is ground glass opacity. Other imaging modalities that are often used are pulmonary computed tomography scan and lung ultrasonography. COVID-19 management in older adults should be comprehensive, starting from oxygen, fluid, nutritional, physical rehabilitation, pharmacology and psychosocial therapy. In this consensus, we also discuss about management of older adults with special condition such as diabetes mellitus, kidney disease, malignancy, frailty, delirium, immobilization and dementia. In post COVID-19 phase, we believe that physical rehabilitation is important as it is done to improve fitness.},
}

Humans
Aged
Middle Aged
*COVID-19/therapy
SARS-CoV-2
Indonesia
*Geriatrics

@article {pmid36989078,
year = {2023},
author = {Melamed, E and Rydberg, L and Ambrose, AF and Bhavaraju-Sanka, R and Fine, JS and Fleming, TK and Herman, E and Phipps Johnson, JL and Kucera, JR and Longo, M and Niehaus, W and Oleson, CV and Sampsel, S and Silver, JK and Smith, MM and Verduzco-Gutierrez, M},
title = {Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of neurologic sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC).},
journal = {PM & R : the journal of injury, function, and rehabilitation},
volume = {15},
number = {5},
pages = {640-662},
doi = {10.1002/pmrj.12976},
pmid = {36989078},
issn = {1934-1563},
mesh = {Humans ; *Post-Acute COVID-19 Syndrome ; *COVID-19 ; SARS-CoV-2 ; Disease Progression ; },
}

Humans
*Post-Acute COVID-19 Syndrome
*COVID-19
SARS-CoV-2
Disease Progression

@article {pmid36599437,
year = {2023},
author = {, and , },
title = {[Chinese consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases (2023)].},
journal = {Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi},
volume = {44},
number = {1},
pages = {19-25},
pmid = {36599437},
issn = {0253-2727},
mesh = {Adult ; Humans ; *COVID-19/prevention & control ; *Hematologic Diseases/complications/therapy ; Vaccination ; China ; *COVID-19 Vaccines/administration & dosage ; },
}

Adult
Humans
*COVID-19/prevention & control
*Hematologic Diseases/complications/therapy
Vaccination
China
*COVID-19 Vaccines/administration & dosage

@article {pmid36549642,
year = {2023},
author = {Cisneros-Serrano, C and Rial, MJ and Gómez-Bastero-Fernández, A and Igea, JM and Martínez-Meca, A and Fernández-Lisón, LC and López-Carrasco, V and Villamañán-Bueno, E and Plá-Martí, MJ and Chiner, E},
title = {Spanish multidisciplinary consensus on the characteristics of severe asthma patients on biologic treatment who are candidates for at-home administration.},
journal = {Revista clinica espanola},
volume = {223},
number = {3},
pages = {154-164},
doi = {10.1016/j.rceng.2022.11.001},
pmid = {36549642},
issn = {2254-8874},
mesh = {Humans ; Pandemics ; *COVID-19 ; *Asthma/diagnosis/drug therapy ; *Biological Products/therapeutic use ; },
abstract = {BACKGROUND AND OBJECTIVE: Biologic therapies are known to reduce exacerbations and improve severe uncontrolled asthma management. The at-home administration of biologics has increased during the COVID-19 pandemic, but the characteristics of severe uncontrolled asthma patients who may benefit from at-home administration of biologic therapy have yet to be identified.

MATERIALS AND METHODS: This project is based on the Delphi method, designed to reach an expert consensus through a multidisciplinary scientific committee addressing the following questions: clinical characteristics, treatment adherence, patient or caregiver administration ability, patient self-care, relationship with the healthcare professional, patient preference, and access to the hospital.

RESULTS: One hundred and thirty-one healthcare professionals (pulmonologists, allergists, nurses, and hospital pharmacists) completed two Delphi consensus questionnaires. Fourteen items were identified as priority characteristics, the first five being: 1. The patient follows the healthcare team's indications/recommendations to control their disease, 2. The patient is capable of detecting any deterioration in their disease and of identifying exacerbation triggers, 3. The patient receives biologic therapy and has stable disease with no vital risk, 4. The patient takes responsibility for their self-care, 5. The patient has occupational/educational obligations that prevent them from going to the hospital regularly.

CONCLUSION: Disease stability and control plus the ability to identify exacerbation triggers are the most important characteristics when opting for at-home administration for a patient with severe uncontrolled asthma on biologic therapy. These recommendations could be applicable in clinical practice.},
}

Humans
Pandemics
*COVID-19
*Asthma/diagnosis/drug therapy
*Biological Products/therapeutic use

@article {pmid36525078,
year = {2023},
author = {Baudouin, R and Hans, S and Guiche, M and Binet, A and Circiu, MP and Crevier-Buchman, L and Morsomme, D and Finck, C and Rutigliano, P and Rodriguez, A and Louvet, NS and Allouche, J and Julien-Laferriere, A and Vialatte de Pemille, G and Bousard, L and de Mones, E and Crestani, S and Giovanni, A and Gallant, N and Lechien, JR},
title = {Tele-rehabilitation in voice disorders during the pandemic: a consensus paper from the French Society of Phoniatrics and Laryngology.},
journal = {European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery},
volume = {280},
number = {5},
pages = {2411-2419},
pmid = {36525078},
issn = {1434-4726},
mesh = {Humans ; *Telerehabilitation ; Reproducibility of Results ; Pandemics ; *Voice Disorders ; *Otolaryngology ; Delphi Technique ; },
abstract = {OBJECTIVES: To establish a consensus protocol for telerehabilitation in speech therapy for voice disorders.

METHODS: The study was conducted according to a modified Delphi method. Twenty speech therapist or laryngologist experts of the French Society of Phoniatrics and Laryngology assessed 24 statements of voice telerehabilitation with a 10-point visual analog scale ranging from 1 (totally disagree) to 10 (totally agree). The statements were accepted if more than 80% of the experts rated the item with a score of ≥ 8/10. The statements with ≥ 8/10 score by 60-80% of experts were improved and resubmitted to voting until they were validated or rejected.

RESULTS: The French Society of Phoniatrics and Laryngology experts validated 10, 6, and 2 statements after the first, second and third voting round, respectively. Seven statements did not reach agreement threshold and were rejected. The validated statements included recommendations for setting (N = 4), medical/speech history (N = 2), subjective voice evaluations (N = 3), objective voice quality measurements (N = 3), and voice rehabilitation (N = 5). The experts agreed for a follow-up consisting of combined telerehabilitation and in-office rehabilitation. The final protocol may be applied in context of pandemic but could be assessed out of pandemic period for patients located in rural regions.

CONCLUSIONS: This Delphi study established the first telerehabilitation protocol of the French Society of Phoniatrics and Laryngology for patients with voice disorders. Future controlled studies are needed to assess its feasibility, reliability, and the patient perception about telerehabilitation versus in-office rehabilitation.},
}

Humans
*Telerehabilitation
Reproducibility of Results
Pandemics
*Voice Disorders
*Otolaryngology
Delphi Technique

@article {pmid36503604,
year = {2022},
author = {Goolsby, C and Schuler, K and Tilley, L and Zebrowski, A and Dacuyan-Faucher, N and Kim, C and Redlener, M},
title = {Military Response to Medical Crises-Consensus Recommendations for Military-Civilian Transitions of Care.},
journal = {Disaster medicine and public health preparedness},
volume = {17},
number = {},
pages = {e281},
doi = {10.1017/dmp.2022.246},
pmid = {36503604},
issn = {1938-744X},
mesh = {Humans ; *Military Personnel ; Pandemics ; *COVID-19/epidemiology ; *Disasters ; Delivery of Health Care ; },
abstract = {OBJECTIVE: The threat that New York faced in 2020, as the COVID-19 pandemic unfolded, prompted an unprecedented response. The US military deployed active-duty medical professionals and equipment to NYC in a first of its kind response to a "medical" domestic disaster. Transitions of care for patients surfaced as a key challenge. Uniformed Services University and the Icahn School of Medicine at Mount Sinai hosted a consensus conference of civilian and military healthcare professionals to identify care transition best practices for future military-civilian responses.

METHODS: We performed individual interviews followed by a modified Delphi technique during a two-day virtual conference. Patient transitions of care emerged as a key theme from pre-conference interviews. Twelve participants attended the two-day virtual conference and generated best practice recommendations from an iterative process.

RESULTS: Participants identified 19 recommendations in 10 "sub-themes" related to patient transitions of care: needs assessment and capability analysis; unified command; equipment; patient handoffs; role of in-person facilitation; dynamic updates; patient selection; patient tracking; daily operations; and resource typing.

CONCLUSIONS: The COVID-19 pandemic resulted in an unprecedented military response. This study created 19 consensus recommendations for care transitions between military and civilian healthcare assets that may be useful in future military-civilian medical engagements.},
}

Humans
*Military Personnel
Pandemics
*COVID-19/epidemiology
*Disasters
Delivery of Health Care

@article {pmid36434156,
year = {2023},
author = {Blagden, SP and Yu, LM and Ellis, S and Hughes, H and Shaaban, A and Fennelly-Barnwell, J and Lythgoe, MP and Cooper, AM and Maignen, FM and Buckland, SW and Kearns, PR and Brown, LC and , },
title = {Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.},
journal = {British journal of cancer},
volume = {128},
number = {3},
pages = {474-477},
pmid = {36434156},
issn = {1532-1827},
support = {MC_UU_00004/02/MRC_/Medical Research Council/United Kingdom ; MC_UU_12023/24/MRC_/Medical Research Council/United Kingdom ; MC_UU_00004/08/MRC_/Medical Research Council/United Kingdom ; MC_UU_00004/01/MRC_/Medical Research Council/United Kingdom ; MC_UU_12023/20/MRC_/Medical Research Council/United Kingdom ; 25354/CRUK_/Cancer Research UK/United Kingdom ; },
mesh = {Humans ; *COVID-19 ; SARS-CoV-2 ; Pandemics ; Medical Oncology ; },
abstract = {In our 2020 consensus paper, we devised ten recommendations for conducting Complex Innovative Design (CID) trials to evaluate cancer drugs. Within weeks of its publication, the UK was hit by the first wave of the SARS-CoV-2 pandemic. Large CID trials were prioritised to compare the efficacy of new and repurposed COVID-19 treatments and inform regulatory decisions. The unusual circumstances of the pandemic meant studies such as RECOVERY were opened almost immediately and recruited record numbers of participants. However, trial teams were required to make concessions and adaptations to these studies to ensure recruitment was rapid and broad. As these are relevant to cancer trials that enrol patients with similar risk factors, we have added three new recommendations to our original ten: employing pragmatism such as using focused information sheets and collection of only the most relevant data; minimising negative environmental impacts with paperless systems; and using direct-to-patient communication methods to improve uptake. These recommendations can be applied to all oncology CID trials to improve their inclusivity, uptake and efficiency. Above all, the success of CID studies during the COVID-19 pandemic underscores their efficacy as tools for rapid treatment evaluation.},
}

Humans
*COVID-19
SARS-CoV-2
Pandemics
Medical Oncology

@article {pmid36319902,
year = {2023},
author = {Alonso, R and Eizaguirre, MB and López, P and Silva, B and Rojas, JI and Sinay, V and Tkachuk, V and Patrucco, L and Carra, A and Bruno, D and Pagani Cassara, F and Fernández Liguori, N and Tavolini, D and Camerlingo, S and Garcea, O and Galiani, A and Mainella, C and Barboza, A and Luetic, G and Carnero Contentti, E},
title = {Argentinean consensus recommendations for the use of telemedicine in clinical practice in adult people with multiple sclerosis.},
journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology},
volume = {44},
number = {2},
pages = {667-676},
pmid = {36319902},
issn = {1590-3478},
mesh = {Humans ; Adult ; *Multiple Sclerosis/diagnosis/therapy/epidemiology ; Pandemics ; *COVID-19 ; *Telemedicine ; Recurrence ; },
abstract = {BACKGROUND: The use of telemedicine has quickly increased during of the COVID-19 pandemic. Given that unmet needs and barriers to multiple sclerosis (MS) care have been reported, telemedicine has become an interesting option to the care of these patients. The objective of these consensus recommendations was to elaborate a guideline for the management of people with MS using telemedicine in order to contribute to an effective and high-quality healthcare.

METHODS: A panel of Argentinean neurologist's experts in neuroimmunological diseases and dedicated to the diagnosis, management,and care of MS patients gathered virtually during 2021 and 2022 to conduct a consensus recommendation on the use of telemedicine in clinical practice in adult people with MS. To reach consensus, the methodology of "formal consensus RAND/UCLA Appropriateness method" was used.

RESULTS: Recommendations were established based on relevant published evidence and expert opinion focusing on definitions, general characteristics and ethical standards, diagnosis of MS, follow-up (evaluation of disability and relapses of MS), identification and treatment of relapses, and finally disease-modifying treatments using telemedicine.

CONCLUSION: The recommendations of this consensus would provide a useful guide for the proper use of telemedicine for the assessment, follow-up, management, and treatment of people with MS. We suggest the use of these guidelines to all the Argentine neurologists committed to the care of people with MS.},
}

Humans
Adult
*Multiple Sclerosis/diagnosis/therapy/epidemiology
Pandemics
*COVID-19
*Telemedicine
Recurrence

@article {pmid36169159,
year = {2022},
author = {Malone, LA and Morrow, A and Chen, Y and Curtis, D and de Ferranti, SD and Desai, M and Fleming, TK and Giglia, TM and Hall, TA and Henning, E and Jadhav, S and Johnston, AM and Kathirithamby, DRC and Kokorelis, C and Lachenauer, C and Li, L and Lin, HC and Locke, T and MacArthur, C and Mann, M and McGrath-Morrow, SA and Ng, R and Ohlms, L and Risen, S and Sadreameli, SC and Sampsel, S and Tejtel, SKS and Silver, JK and Simoneau, T and Srouji, R and Swami, S and Torbey, S and Gutierrez, MV and Williams, CN and Zimmerman, LA and Vaz, LE},
title = {Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of postacute sequelae of SARS-CoV-2 infection (PASC) in children and adolescents.},
journal = {PM & R : the journal of injury, function, and rehabilitation},
volume = {14},
number = {10},
pages = {1241-1269},
doi = {10.1002/pmrj.12890},
pmid = {36169159},
issn = {1934-1563},
support = {K23 HL150229/HL/NHLBI NIH HHS/United States ; },
mesh = {Child ; Humans ; Adolescent ; *COVID-19 ; SARS-CoV-2 ; Disease Progression ; },
}

Child
Humans
Adolescent
*COVID-19
SARS-CoV-2
Disease Progression

@article {pmid36169154,
year = {2022},
author = {Blitshteyn, S and Whiteson, JH and Abramoff, B and Azola, A and Bartels, MN and Bhavaraju-Sanka, R and Chung, T and Fleming, TK and Henning, E and Miglis, MG and Sampsel, S and Silver, JK and Tosto, J and Verduzco-Gutierrez, M and Putrino, D},
title = {Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with post-acute sequelae of SARS-CoV-2 infection (PASC).},
journal = {PM & R : the journal of injury, function, and rehabilitation},
volume = {14},
number = {10},
pages = {1270-1291},
doi = {10.1002/pmrj.12894},
pmid = {36169154},
issn = {1934-1563},
mesh = {Humans ; *COVID-19 ; SARS-CoV-2 ; *Primary Dysautonomias ; Disease Progression ; Post-Acute COVID-19 Syndrome ; },
}

Humans
*COVID-19
SARS-CoV-2
*Primary Dysautonomias
Disease Progression
Post-Acute COVID-19 Syndrome

@article {pmid36137091,
year = {2022},
author = {Yiasemidou, M and Howitt, A and Long, J and Sedman, P and Garcia-Olmo, D and Guadalajara, H and Van Cleynenbreugel, B and Sharma, D and Biyani, SC and Patel, B and Lam, W and Harikrishnan, A and Gómez Rivas, J and Robinson, J and Manuel Ribeiro de Oliveira, T and Escalona Vivas, G and Sanchez-Salas, R and Tourinho-Barbosa, R and Chetter, I},
title = {An international consensus for mitigation of the detrimental effects of the COVID-19 pandemic on laparoscopic training.},
journal = {PloS one},
volume = {17},
number = {9},
pages = {e0272446},
pmid = {36137091},
issn = {1932-6203},
mesh = {*COVID-19/epidemiology ; Delphi Technique ; Humans ; *Laparoscopy/education ; Pandemics ; },
abstract = {AIM: Achieve an international consensus on how to recover lost training opportunities. The results of this study will help inform future EAES guidelines about the recovery of surgical training before and after the pandemic.

BACKGROUND: A global survey conducted by our team demonstrated significant disruption in surgical training during the COVID-19 pandemic. This was wide-spread and affected all healthcare systems (whether insurance based or funded by public funds) in all participating countries. Thematic analysis revealed the factors perceived by trainees as barriers to training and gave birth to four-point framework of recovery. These are recommendations that can be easily achieved in any country, with minimal resources. Their implementation, however, relies heavily on the active participation and leadership by trainers. Based on the results of the global trainee survey, the authors would like to conduct a Delphi-style survey, addressed to trainers on this occasion, to establish a pragmatic step-by-step approach to improve training during and after the pandemic.

METHODS: This will be a mixed qualitative and quantitative study. Semi-structured interviews will be performed with laparoscopic trainers. These will be transcribed and thematic analysis will be applied. A questionnaire will then be proposed; this will be based on both the results of the semi structured interviews and of the global trainee survey. The questionnaire will then be validated by the steering committee of this group (achieve consensus of >80%). After validation, the questionnaire will be disseminated to trainers across the globe. Participants will be asked to consent to participate in further cycles of the Delphi process until more than 80% agreement is achieved.

RESULTS: This study will result in a pragmatic framework for continuation of surgical training during and after the pandemic (with special focus on minimally invasive surgery training).},
}

*COVID-19/epidemiology
Delphi Technique
Humans
*Laparoscopy/education
Pandemics

@article {pmid35697565,
year = {2022},
author = {Calle Rubio, M and López-Campos, JL and Izquierdo Alonso, JL and Martínez Pitarch, D and Pascual, MI and Navarrete, BA and Falcones, MV and Inglés, MJA and López, CC and Martínez, CJÁ and Ruiz, FO and Golpe, R and Gomila, AF and Guardia, SP and Miranda, JAR and Peces-Barba, G and García-Río, F and Muñiz, MÁM and Cosío, BG},
title = {Consensus on the Management of the COPD Patient in the COVID-19 Setting: COPD Forum Working Group.},
journal = {Archivos de bronconeumologia},
volume = {58},
number = {11},
pages = {776-779},
pmid = {35697565},
issn = {1579-2129},
mesh = {Humans ; *COVID-19 ; *Pulmonary Disease, Chronic Obstructive/complications/therapy ; },
}

Humans
*COVID-19
*Pulmonary Disease, Chronic Obstructive/complications/therapy

@article {pmid35657351,
year = {2022},
author = {Whiteson, JH and Azola, A and Barry, JT and Bartels, MN and Blitshteyn, S and Fleming, TK and McCauley, MD and Neal, JD and Pillarisetti, J and Sampsel, S and Silver, JK and Terzic, CM and Tosto, J and Verduzco-Gutierrez, M and Putrino, D},
title = {Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC).},
journal = {PM & R : the journal of injury, function, and rehabilitation},
volume = {14},
number = {7},
pages = {855-878},
pmid = {35657351},
issn = {1934-1563},
support = {I01 BX004918/BX/BLRD VA/United States ; R01 HL151508/HL/NHLBI NIH HHS/United States ; },
mesh = {*COVID-19/complications ; Disease Progression ; Humans ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; },
}

*COVID-19/complications
Disease Progression
Humans
SARS-CoV-2
Post-Acute COVID-19 Syndrome

@article {pmid35544441,
year = {2023},
author = {Gannon, WD and Trindade, AJ and Stokes, JW and Casey, JD and Benson, C and Patel, YJ and Pugh, ME and Semler, MW and Bacchetta, M and Rice, TW},
title = {Extracorporeal Membrane Oxygenation Selection by Multidisciplinary Consensus: The ECMO Council.},
journal = {ASAIO journal (American Society for Artificial Internal Organs : 1992)},
volume = {69},
number = {2},
pages = {167-173},
doi = {10.1097/MAT.0000000000001757},
pmid = {35544441},
issn = {1538-943X},
mesh = {Adult ; Humans ; Middle Aged ; *COVID-19/therapy ; *Extracorporeal Membrane Oxygenation/methods ; Retrospective Studies ; Patient Selection ; *Respiratory Distress Syndrome/therapy ; },
abstract = {Coronavirus disease 2019 (COVID-19) has increased the demand for extracorporeal membrane oxygenation (ECMO) and introduced distinct challenges to patient selection for ECMO. Standardized processes for patient selection amidst resource limitations are lacking, and data on ECMO consults are underreported. We retrospectively reviewed consecutive adult ECMO consults for acute respiratory failure received at a single academic medical center from April 1, 2020, to February 28, 2021, and evaluated the implementation of a multidisciplinary selection committee (ECMO Council) and standardized framework for patient selection for ECMO. During the 334-day period, there were 202 total ECMO consults; 174 (86.1%) included a diagnosis of COVID-19. Among all consults, 157 (77.7%) were declined and 41 (20.3%) resulted in the initiation of ECMO. Frequent reasons for decline included the presence of multiple relative contraindications (n = 33), age greater than 60 years (n = 32), and resource limitations (n = 27). The ECMO Council deliberated on every case in which an absolute contraindication was not present (n = 96) via an electronic teleconference platform. Utilizing multidisciplinary consensus together with a standardized process for patient selection in ECMO is feasible during a pandemic and may be reliably exercised over time. Whether such an approach is feasible at other centers remains unknown.},
}

Adult
Humans
Middle Aged
*COVID-19/therapy
*Extracorporeal Membrane Oxygenation/methods
Retrospective Studies
Patient Selection
*Respiratory Distress Syndrome/therapy

@article {pmid35484667,
year = {2022},
author = {Wang, ZM and Liu, Q and Liu, YX and Chen, YJ and Zhou, Q and Deng, XL and Zhang, XD and Xu, BH and Zhu, YQ and Gao, CZ and Yin, L and Xie, H and Fei, W and Zhou, J and Yuan, CQ and He, XN and Wang, X and Chen, LL},
title = {[Consensus of experts on the oral health management and medical risk prevention for the patients with chronic airway diseases (2022 edition)].},
journal = {Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology},
volume = {57},
number = {5},
pages = {455-461},
doi = {10.3760/cma.j.cn112144-20220228-00081},
pmid = {35484667},
issn = {1002-0098},
mesh = {*COVID-19 ; Humans ; Oral Health ; *Oral Medicine ; },
abstract = {Today, there is greater awareness on the association between oral diseases and respiration diseases after the outbreak of COVID-19. However, confusion regarding the oral health management and medical risk prevention for patients with chronic airway diseases has been remained among dental clinicians. Therefore, the dental experts of the Fifth General Dentistry Special Committee, Chinese Stomatological Association, combined with the experts of respiratory and critical care medicine, undertook the formation of consensus on the oral health management of patients with chronic airway diseases in order to help dental clinicians to evaluate medical risks and make better treatment decision in clinical practice. In the present consensus report, the relationship of oral diseases and chronic airway diseases, the oral health management and the treatment recommendations of patients with chronic airway diseases are provided.},
}

*COVID-19
Humans
Oral Health
*Oral Medicine

@article {pmid35441203,
year = {2022},
author = {Gao, J and Lun, P and Ding, YY and George, PP},
title = {COVID-19 Vaccination for Frail Older Adults in Singapore - Rapid Evidence Summary and Delphi Consensus Statements.},
journal = {The Journal of frailty & aging},
volume = {11},
number = {2},
pages = {236-241},
pmid = {35441203},
issn = {2260-1341},
mesh = {Aged ; *COVID-19/epidemiology/prevention & control ; *COVID-19 Vaccines/adverse effects ; Clinical Trials, Phase III as Topic ; Delphi Technique ; Frail Elderly ; Humans ; Randomized Controlled Trials as Topic ; Singapore/epidemiology ; Vaccination ; },
abstract = {OBJECTIVE: This study aimed to synthesize available evidence on the effectiveness and safety of COVID-19 vaccines for frail older adults through a rapid review, supplemented with geriatricians' consensus statements.

METHODS: References were identified through MEDLINE and Web of Science on 1st February 2021 using relevant terms related to COVID-19, vaccine, and older adults. Searches were also conducted on reference lists of review articles and Google Scholar. The content was updated on 8th April via hand searching. We included studies on Phase III randomized controlled trials, and data from real world administration of vaccines. A two-round Delphi study was conducted with 15 geriatricians to elicit their thoughts and recommendations regarding COVID-19 vaccination for frail older adults.

RESULTS: Five Phase III randomized controlled efficacy trials reported vaccine efficacy ranging from 66.7% to 95% among participants aged 16 to 95. The vaccine efficacy for participants aged 65 and above is 94.7% and 86.4% for Pfizer-BioNTech and Moderna respectively. Sputnik V reported a vaccine efficacy of 91.8% for participants 60 and above. Serious adverse events were reported by 0.27% to 1% of participants who received at least one dose of the four vaccines. For the Delphi study, 16 out of 24 statements achieved consensus. The Delphi panel opined that frail or very old adults, except those with limited life expectancy, should be vaccinated due to their vulnerability. They also agree that vaccination decisions should be made by patients when possible, with the involvement of next-of-kin should the frail older adult be unable to do so. Lastly, the panel thought that frail older adults should be included in future clinical trials.

CONCLUSION: In early clinical trials, there is paucity of evidence on efficacy and safety of current COVID-19 vaccines among frail older adults. Geriatricians' consensus indicate that frail older adults should be vaccinated except where life expectancy is limited. Future trials assessing efficacy and safety should include frail older adults.},
}

Aged
*COVID-19/epidemiology/prevention & control
*COVID-19 Vaccines/adverse effects
Clinical Trials, Phase III as Topic
Delphi Technique
Frail Elderly
Humans
Randomized Controlled Trials as Topic
Singapore/epidemiology
Vaccination

@article {pmid35393158,
year = {2022},
author = {Turco, F and Armstrong, A and Attard, G and Beer, TM and Beltran, H and Bjartell, A and Bossi, A and Briganti, A and Bristow, RG and Bulbul, M and Caffo, O and Chi, KN and Clarke, C and Clarke, N and Davis, ID and de Bono, J and Duran, I and Eeles, R and Efstathiou, E and Efstathiou, J and Evans, CP and Fanti, S and Feng, FY and Fizazi, K and Frydenberg, M and George, D and Gleave, M and Halabi, S and Heinrich, D and Higano, C and Hofman, MS and Hussain, M and James, N and Jones, R and Kanesvaran, R and Khauli, RB and Klotz, L and Leibowitz, R and Logothetis, C and Maluf, F and Millman, R and Morgans, AK and Morris, MJ and Mottet, N and Mrabti, H and Murphy, DG and Murthy, V and Oh, WK and Ekeke Onyeanunam, N and Ost, P and O'Sullivan, JM and Padhani, AR and Parker, C and Poon, DMC and Pritchard, CC and Rabah, DM and Rathkopf, D and Reiter, RE and Rubin, M and Ryan, CJ and Saad, F and Pablo Sade, J and Sartor, O and Scher, HI and Shore, N and Skoneczna, I and Small, E and Smith, M and Soule, H and Spratt, D and Sternberg, CN and Suzuki, H and Sweeney, C and Sydes, M and Taplin, ME and Tilki, D and Tombal, B and Türkeri, L and Uemura, H and Uemura, H and van Oort, I and Yamoah, K and Ye, D and Zapatero, A and Gillessen, S and Omlin, A},
title = {What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.},
journal = {European urology},
volume = {82},
number = {1},
pages = {6-11},
pmid = {35393158},
issn = {1873-7560},
support = {MC_UU_00004/02/MRC_/Medical Research Council/United Kingdom ; MC_UU_00004/08/MRC_/Medical Research Council/United Kingdom ; MC_UU_12023/28/MRC_/Medical Research Council/United Kingdom ; },
mesh = {Androgen Antagonists/therapeutic use ; *COVID-19 ; COVID-19 Vaccines ; Humans ; Male ; Pandemics/prevention & control ; *Prostatic Neoplasms/pathology ; },
abstract = {Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. PATIENT SUMMARY: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.},
}

Androgen Antagonists/therapeutic use
*COVID-19
COVID-19 Vaccines
Humans
Male
Pandemics/prevention & control
*Prostatic Neoplasms/pathology

@article {pmid35359262,
year = {2022},
author = {Fiest, KM and Krewulak, KD and Hernández, LC and Jaworska, N and Makuk, K and Schalm, E and Bagshaw, SM and Bernet, X and Burns, KEA and Couillard, P and Doig, CJ and Fowler, R and Kho, ME and Kupsch, S and Lauzier, F and Niven, DJ and Oggy, T and Rewa, OG and Rochwerg, B and Spence, S and West, A and Stelfox, HT and Parsons Leigh, J and , },
title = {Evidence-informed consensus statements to guide COVID-19 patient visitation policies: results from a national stakeholder meeting.},
journal = {Canadian journal of anaesthesia = Journal canadien d'anesthesie},
volume = {69},
number = {7},
pages = {868-879},
pmid = {35359262},
issn = {1496-8975},
mesh = {*COVID-19 ; Canada ; Humans ; Intensive Care Units ; Pandemics/prevention & control ; Policy ; *Visitors to Patients ; },
abstract = {PURPOSE: Hospital policies forbidding or limiting families from visiting relatives on the intensive care unit (ICU) has affected patients, families, healthcare professionals, and patient- and family-centered care (PFCC). We sought to refine evidence-informed consensus statements to guide the creation of ICU visitation policies during the current COVID-19 pandemic and future pandemics and to identify barriers and facilitators to their implementation and sustained uptake in Canadian ICUs.

METHODS: We created consensus statements from 36 evidence-informed experiences (i.e., impacts on patients, families, healthcare professionals, and PFCC) and 63 evidence-informed strategies (i.e., ways to improve restricted visitation) identified during a modified Delphi process (described elsewhere). Over two half-day virtual meetings on 7 and 8 April 2021, 45 stakeholders (patients, families, researchers, clinicians, decision-makers) discussed and refined these consensus statements. Through qualitative descriptive content analysis, we evaluated the following points for 99 consensus statements: 1) their importance for improving restricted visitation policies; 2) suggested modifications to make them more applicable; and 3) facilitators and barriers to implementing these statements when creating ICU visitation policies.

RESULTS: Through discussion, participants identified three areas for improvement: 1) clarity, 2) accessibility, and 3) feasibility. Stakeholders identified several implementation facilitators (clear, flexible, succinct, and prioritized statements available in multiple modes), barriers (perceived lack of flexibility, lack of partnership between government and hospital, change fatigue), and ways to measure and monitor their use (e.g., family satisfaction, qualitative interviews).

CONCLUSIONS: Existing guidance on policies that disallowed or restricted visitation in intensive care units were confusing, hard to operationalize, and often lacked supporting evidence. Prioritized, succinct, and clear consensus statements allowing for local adaptability are necessary to guide the creation of ICU visitation policies and to optimize PFCC.},
}

*COVID-19
Canada
Humans
Intensive Care Units
Pandemics/prevention & control
Policy
*Visitors to Patients

@article {pmid35249855,
year = {2022},
author = {Morales-García, D and Docobo-Durantez, F and Capitán Vallvey, JM and Suarez-Grau, JM and Campo-Cimarras, ME and González-Vinagre, S and Hidalgo-Grau, LA and Puigcercos-Fusté, JM and Zaragoza-Fernández, C and Valera-Sánchez, Z and Vega-Ruiz, V and , },
title = {Consensus of the ambulatory surgery commite section of the Spanish Association of Surgeons on the role of ambulatory surgery in the SARS-CoV-2 pandemic.},
journal = {Cirugia espanola},
volume = {100},
number = {3},
pages = {115-124},
pmid = {35249855},
issn = {2173-5077},
mesh = {Ambulatory Surgical Procedures ; *COVID-19 ; Humans ; Pandemics ; SARS-CoV-2 ; *Surgeons ; },
abstract = {The current situation of the SARS-CoV-2 pandemic has paralyzed non-urgent and/or oncological surgery in many hospitals in our country with what it means for the health of citizens who are awaiting a surgical procedure. Outpatient Surgery can afford more than 85% of the surgical procedures that are performed in a surgical department and is presented as a feasible and safe alternative at the present time since it does not require admission and decreases clearly the risk of infection. In addition, it is the tool that should be generalized to solve the accumulation of patients on the waiting list that the pandemic is generating, so it seems appropriate that the Ambulatory Surgery section of the Spanish Association of Surgeons present a series of recommendations for the implementation of outpatient surgery in these exceptional circumstances that we have to live.},
}

Ambulatory Surgical Procedures
*COVID-19
Humans
Pandemics
SARS-CoV-2
*Surgeons

@article {pmid35244174,
year = {2022},
author = {Stevens, KI and Frangou, E and Shin, JIL and Anders, HJ and Bruchfeld, A and Schönermarck, U and Hauser, T and Westman, K and Fernandez-Juarez, GM and Floege, J and Goumenos, D and Turkmen, K and van Kooten, C and McAdoo, SP and Tesar, V and Segelmark, M and Geetha, D and Jayne, DRW and Kronbichler, A and , },
title = {Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS.},
journal = {Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
volume = {37},
number = {8},
pages = {1400-1410},
pmid = {35244174},
issn = {1460-2385},
mesh = {Antibodies, Viral ; COVID-19/prevention & control ; *COVID-19 Vaccines/adverse effects/immunology ; Humans ; *Kidney Diseases/drug therapy/immunology ; Mycophenolic Acid/therapeutic use ; Rituximab/therapeutic use ; },
abstract = {Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or comorbidities and complications caused by the underlying disease. Humoral vaccine response, measured by the presence of antibodies, is impaired or absent in patients receiving rituximab, mycophenolate mofetil (MMF), higher doses of glucocorticoids and likely other immunosuppressants, such as cyclophosphamide. The timing between the use of these agents and administration of vaccines is associated with the level of immune response: with rituximab, vaccine response can only be expected once B cells start to recover and patients with transient discontinuation of MMF mount a humoral response more frequently. The emergence of new COVID-19 variants and waning of vaccine-induced immunity highlight the value of a booster dose and the need to develop mutant-proof vaccines. COVID-19 vaccines are safe, exhibiting a very low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.},
}

Antibodies, Viral
COVID-19/prevention & control
*COVID-19 Vaccines/adverse effects/immunology
Humans
*Kidney Diseases/drug therapy/immunology
Mycophenolic Acid/therapeutic use
Rituximab/therapeutic use

@article {pmid35175578,
year = {2022},
author = {Biancone, L and Minetti, E and De Rosa, P and Rigotti, P and Stallone, G and Volpe, M and Citterio, F},
title = {Telemedicine monitoring in the follow-up of kidney transplant recipients: consensus indications from an Italian panel of surgeons and nephrologists after the COVID-19 experience.},
journal = {Journal of nephrology},
volume = {35},
number = {3},
pages = {725-733},
pmid = {35175578},
issn = {1724-6059},
mesh = {*COVID-19/epidemiology ; Follow-Up Studies ; Humans ; *Kidney Transplantation ; Nephrologists ; Pandemics ; *Surgeons ; *Telemedicine/methods ; Transplant Recipients ; },
abstract = {The quality of follow-up has clearly emerged as a key factor for long-term kidney graft survival. Currently, many clinics are facing difficulties in delivering optimal surveillance because of the increased number and complexity of kidney transplant recipients, and because of the COVID-19 pandemic. Additional ways of performing follow-up visits are needed and telemedicine has emerged as a tool to strengthen patient care intensity. Six Italian transplant surgeons and nephrologists convened via teleconference to develop a consensual model of video visits for the follow-up of kidney transplant recipients. Issues discussed were: profile of eligible patients; assessments that can be carried out; video visit organization and medical professionals involved; supporting tools and implementation. The video visit was consensually recognized as the most relevant for the follow-up of kidney transplant recipients. Eligible patients should have basic electronic devices and the skills to correctly use them and be in clinically stable condition. With the exception of physical and instrumental examination, and kidney biopsy, all other assessments are feasible during a video visit and can be implemented by specific training and use of supporting tools. The video visit model is simple and adaptable to most transplant patients. It is not intended to replace face-to-face examinations, but is an additional tool for improving the intensity of follow-up of kidney transplant recipients, which can be integrated into current monitoring protocols.},
}

*COVID-19/epidemiology
Follow-Up Studies
Humans
*Kidney Transplantation
Nephrologists
Pandemics
*Surgeons
*Telemedicine/methods
Transplant Recipients

@article {pmid35130362,
year = {2022},
author = {Eriksson, E and Liu, PY and Schultz, GS and Martins-Green, MM and Tanaka, R and Weir, D and Gould, LJ and Armstrong, DG and Gibbons, GW and Wolcott, R and Olutoye, OO and Kirsner, RS and Gurtner, GC},
title = {Chronic wounds: Treatment consensus.},
journal = {Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society},
volume = {30},
number = {2},
pages = {156-171},
pmid = {35130362},
issn = {1524-475X},
support = {R01 DK124789/DK/NIDDK NIH HHS/United States ; },
mesh = {*COVID-19/therapy ; Humans ; Pandemics ; Quality of Life ; *Wound Healing ; },
abstract = {The Wound Healing Foundation (WHF) recognised a need for an unbiased consensus on the best treatment of chronic wounds. A panel of 13 experts were invited to a virtual meeting which took place on 27 March 2021. The proceedings were organised in the sub-sections diagnosis, debridement, infection control, dressings, grafting, pain management, oxygen treatment, outcomes and future needs. Eighty percent or better concurrence among the panellists was considered a consensus. A large number of critical questions were discussed and agreed upon. Important takeaways included that wound care needs to be simplified to a point that it can be delivered by the patient or the patient's family. Another one was that telemonitoring, which has proved very useful during the COVID-19 pandemic, can help reduce the frequency of interventions by a visiting nurse or a wound care center. Defining patient expectations is critical to designing a successful treatment. Patient outcomes might include wound specific outcomes such as time to heal, wound size reduction, as well as improvement in quality of life. For those patients with expectations of healing, an aggressive approach to achieve that goal is recommended. When healing is not an expectation, such as in patients receiving palliative wound care, outcomes might include pain reduction, exudate management, odour management and/or other quality of life benefits to wound care.},
}

*COVID-19/therapy
Humans
Pandemics
Quality of Life
*Wound Healing

@article {pmid35074360,
year = {2022},
author = {Duque, G and Iuliano, S and Close, JCT and Fatima, M and Ganda, K and Bird, S and Kirk, B and Levidiotis, M and Said, CM and Papaioannou, A and Inderjeeth, CA},
title = {Prevention of Osteoporotic Fractures in Residential Aged Care: Updated Consensus Recommendations.},
journal = {Journal of the American Medical Directors Association},
volume = {23},
number = {5},
pages = {756-763},
doi = {10.1016/j.jamda.2021.12.041},
pmid = {35074360},
issn = {1538-9375},
mesh = {Aged ; *Assisted Living Facilities ; *COVID-19 ; Humans ; *Osteoporosis/prevention & control ; *Osteoporotic Fractures/epidemiology/prevention & control ; Pandemics ; },
abstract = {Osteoporosis is underdiagnosed and undertreated in people living in Residential Aged Care Facilities (RACFs), even though aged-care residents are at greater risk of experiencing fractures than their community-dwelling counterparts. The first (2009) and second (2016) Consensus Conferences on the Treatment of Osteoporosis in RACFs in Australia addressed the prevention of falls and fractures in RACFs. A third Consensus Conference was held to review advances in the field of osteoporosis for people living in RACFs and to update current guidelines. The Conference was held virtually in October 2020 due to the COVID-19 pandemic. Attendance at the meeting was open to health practitioners (n = 116) (eg, general practitioners, geriatricians, rehabilitation specialists, endocrinologists, pharmacists, and physiotherapists) working in RACFs. Participants chose and/or were assigned to breakout groups to review the evidence and reach a consensus on the topic area assigned to the group, which was then presented to the entire group by a nominated spokesperson. Recommendations developed by breakout groups were discussed and voted on by all attending participants. This article updates the evidence for preventing falls and fractures and managing osteoporosis in older adults living in RACFs based on agreed outcomes from the group. We anticipate these updated recommendations will provide health practitioners with valuable guidance when practicing in RACFs.},
}

Aged
*Assisted Living Facilities
*COVID-19
Humans
*Osteoporosis/prevention & control
*Osteoporotic Fractures/epidemiology/prevention & control
Pandemics

@article {pmid35064982,
year = {2022},
author = {Schoenfeld, EM and Lin, MP and Samuels-Kalow, ME},
title = {Executive summary of the 2021 SAEM consensus conference: From bedside to policy: Advancing social emergency medicine and population health through research, collaboration, and education.},
journal = {Academic emergency medicine : official journal of the Society for Academic Emergency Medicine},
volume = {29},
number = {3},
pages = {354-363},
pmid = {35064982},
issn = {1553-2712},
support = {K08 HS025701/HS/AHRQ HHS/United States ; K23 HL143042/HL/NHLBI NIH HHS/United States ; K23HL143042-01A1/HL/NHLBI NIH HHS/United States ; 1K08HS025701-01A1//Agency for Healthcare Research and Quality/ ; },
mesh = {*COVID-19 ; *Emergency Medicine/education ; Humans ; Pandemics ; Policy ; *Population Health ; },
abstract = {BACKGROUND: Social emergency medicine (social EM) examines the intersection of emergency care and the social factors that influence health outcomes. In 2021, the SAEM consensus conference focused on social EM and population health, with the goal of prioritizing research topics, creating collaborations, and advancing the field of social EM.

METHODS: Organization of the conference began in 2019 within SAEM. Cochairs were identified and a planning committee created the framework for the conference. Leaders for subgroups were identified, and subgroups performed literature reviews and identified additional stakeholders within EM and community organizations. As a result of the COVID-19 pandemic, the conference format was modified.

RESULTS: A total of 246 participants registered for the conference and participated in some capacity at three distinct online sessions. Research prioritization subgroups were as follows-group 1: ED screening and referral for social and access needs; group 2: structural competency; and group 3: race, racism, and antiracism. Thirty-two "projects in progress" were presented within five domains-identity and health: people and places; health care systems; training and education; material needs; and individual and structural violence.

CONCLUSIONS: Despite ongoing challenges posed by the COVID-19 pandemic, the 2021 SAEM consensus conference brought together hundreds of stakeholders to define research priorities and create collaborations to push the field forward.},
}

*COVID-19
*Emergency Medicine/education
Humans
Pandemics
Policy
*Population Health

@article {pmid35044509,
year = {2022},
author = {Kremer, S and Gerevini, S and Ramos, A and Lersy, F and Yousry, T and Vernooij, MW and Anzalone, N and Jäger, HR},
title = {Neuroimaging in patients with COVID-19: a neuroradiology expert group consensus.},
journal = {European radiology},
volume = {32},
number = {6},
pages = {3716-3725},
pmid = {35044509},
issn = {1432-1084},
support = {MR/M009106/1/MRC_/Medical Research Council/United Kingdom ; },
mesh = {*COVID-19 ; Gadolinium ; Humans ; Magnetic Resonance Imaging/methods ; Neuroimaging/methods ; },
abstract = {Neurological and neuroradiological manifestations in patients with COVID-19 have been extensively reported. Available imaging data are, however, very heterogeneous. Hence, there is a growing need to standardise clinical indications for neuroimaging, MRI acquisition protocols, and necessity of follow-up examinations. A NeuroCovid working group with experts in the field of neuroimaging in COVID-19 has been constituted under the aegis of the Subspecialty Committee on Diagnostic Neuroradiology of the European Society of Neuroradiology (ESNR). The initial objectives of this NeuroCovid working group are to address the standardisation of the imaging in patients with neurological manifestations of COVID-19 and to give advice based on expert opinion with the aim of improving the quality of patient care and ensure high quality of any future clinical studies. KEY POINTS: • In patients with COVID-19 and neurological manifestations, neuroimaging should be performed in order to detect underlying causal pathology. • The basic MRI recommended protocol includes T2-weighted, FLAIR (preferably 3D), and diffusion-weighted images, as well as haemorrhage-sensitive sequence (preferably SWI), and at least for the initial investigation pre and post-contrast T1 weighted-images. • 3D FLAIR should be acquired after gadolinium administration in order to optimise the detection of leptomeningeal contrast enhancement.},
}

*COVID-19
Gadolinium
Humans
Magnetic Resonance Imaging/methods
Neuroimaging/methods

@article {pmid35025726,
year = {2022},
author = {Le, AB and Brown, CK and Gibbs, SG and Uhrig, A and Green, AD and Broch Brantsæter, A and Herstein, JJ and Vasa, A and Shugart, J and Wilson Egbe, W and Lowe, JJ},
title = {Best practices of highly infectious decedent management: Consensus recommendations from an international expert workshop.},
journal = {Journal of occupational and environmental hygiene},
volume = {19},
number = {3},
pages = {129-138},
doi = {10.1080/15459624.2022.2027427},
pmid = {35025726},
issn = {1545-9632},
mesh = {*Communicable Diseases/epidemiology ; *Hemorrhagic Fever, Ebola ; Humans ; Infection Control ; Pandemics/prevention & control ; },
abstract = {With the increasing number of highly infectious disease incidents, outbreaks, and pandemics in our society (e.g., Ebola virus disease, Lassa fever, coronavirus diseases), the need for consensus and best practices on highly infectious decedent management is critical. In January 2020, a workshop of subject matter experts from across the world convened to discuss highly infectious live patient transport and highly infectious decedent management best practices. This commentary focuses on the highly infectious decedent management component of the workshop. The absence of guidance or disparate guidance on highly infectious decedent management can increase occupational safety and health risks for death care sector workers. To address this issue, the authorship presents these consensus recommendations on best practices in highly infectious decedent management, including discussion of what is considered a highly infectious decedent; scalability and storage for casualty events; integration of key stakeholders; infection control and facility considerations; transport; care and autopsy; psychological, ethical, and cultural considerations as well as multi-national care perspectives. These consensus recommendations are not intended to be exhaustive but rather to underscore this overlooked area and serve as a starting point for much-needed conversations.},
}

*Communicable Diseases/epidemiology
*Hemorrhagic Fever, Ebola
Humans
Infection Control
Pandemics/prevention & control

@article {pmid34940084,
year = {2021},
author = {Cheung, MC and Franco, BB and Meti, N and Thawer, A and Tahmasebi, H and Shankar, A and Loblaw, A and Wright, FC and Fox, C and Peek, N and Sim, V and Singh, S},
title = {Delivery of Virtual Care in Oncology: Province-Wide Interprofessional Consensus Statements Using a Modified Delphi Process.},
journal = {Current oncology (Toronto, Ont.)},
volume = {28},
number = {6},
pages = {5332-5345},
pmid = {34940084},
issn = {1718-7729},
support = {00420398//CIHR/Canada ; },
mesh = {*COVID-19 ; Delphi Technique ; Humans ; *Pandemics ; SARS-CoV-2 ; },
abstract = {Virtual cancer care (i.e., teleoncology) was rapidly adopted during the COVID-19 pandemic to meet the needs of patients with cancer. However, there is a paucity of guidance for clinicians regarding virtual cancer care. We sought to develop consensus-based statements to guide the optimal provision of virtual care for clinicians caring for patients with cancer, using a modified Delphi consensus process with a 29-member panel consisting of an interprofessional group of clinicians caring for patients with cancer and patient representatives. The consensus process consisted of two rounds and one synchronous final consensus meeting. At the end of the modified Delphi process, 62 of 62 statements achieved consensus. Fifty-seven statements reached consensus in the first round of the process. Concerns regarding the ability to convey difficult news virtually and maintaining similar standards as in-person care without disproportionate strain on clinicians and patients were addressed in the consensus process. We achieved interprofessional consensus on virtual cancer care practices. Further research examining the impact of virtual cancer care on person-centred and clinical outcomes are needed to inform practices during the COVID-19 pandemic and beyond.},
}

*COVID-19
Delphi Technique
Humans
*Pandemics
SARS-CoV-2

@article {pmid34902226,
year = {2022},
author = {Fine, JS and Ambrose, AF and Didehbani, N and Fleming, TK and Glashan, L and Longo, M and Merlino, A and Ng, R and Nora, GJ and Rolin, S and Silver, JK and Terzic, CM and Verduzco-Gutierrez, M and Sampsel, S},
title = {Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cognitive symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC).},
journal = {PM & R : the journal of injury, function, and rehabilitation},
volume = {14},
number = {1},
pages = {96-111},
doi = {10.1002/pmrj.12745},
pmid = {34902226},
issn = {1934-1563},
mesh = {*COVID-19/complications ; Cognition ; Humans ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; },
}

*COVID-19/complications
Cognition
Humans
SARS-CoV-2
Post-Acute COVID-19 Syndrome

@article {pmid34902224,
year = {2022},
author = {Maley, JH and Alba, GA and Barry, JT and Bartels, MN and Fleming, TK and Oleson, CV and Rydberg, L and Sampsel, S and Silver, JK and Sipes, S and Verduzco-Gutierrez, M and Wood, J and Zibrak, JD and Whiteson, J},
title = {Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC).},
journal = {PM & R : the journal of injury, function, and rehabilitation},
volume = {14},
number = {1},
pages = {77-95},
doi = {10.1002/pmrj.12744},
pmid = {34902224},
issn = {1934-1563},
mesh = {*COVID-19/complications ; Disease Progression ; Humans ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; },
}

*COVID-19/complications
Disease Progression
Humans
SARS-CoV-2
Post-Acute COVID-19 Syndrome

@article {pmid34776407,
year = {2021},
author = {Llau, JV and Ferrandis, R and Sierra, P and Hidalgo, F and Cassinello, C and Gómez-Luque, A and Quintana, M and Amezaga, R and Geroi, M and Serrano, A and Marcos, P},
title = {SEDAR-SEMICYUC consensus on the management of haemostasis disorders in severe COVID-19 patients.},
journal = {Medicina intensiva},
volume = {45},
number = {9},
pages = {567-568},
pmid = {34776407},
issn = {2173-5727},
mesh = {*Blood Coagulation Disorders/therapy ; *COVID-19 ; Hemostasis ; Humans ; SARS-CoV-2 ; },
}

*Blood Coagulation Disorders/therapy
*COVID-19
Hemostasis
Humans
SARS-CoV-2

@article {pmid34639553,
year = {2021},
author = {Chater, AM and Shorter, GW and Swanson, V and Kamal, A and Epton, T and Arden, MA and Hart, J and Byrne-Davis, LMT and Drury, J and Whittaker, E and Lewis, LJM and McBride, E and Chadwick, P and O'Connor, DB and Armitage, CJ},
title = {Template for Rapid Iterative Consensus of Experts (TRICE).},
journal = {International journal of environmental research and public health},
volume = {18},
number = {19},
pages = {},
pmid = {34639553},
issn = {1660-4601},
mesh = {*COVID-19 ; Delivery of Health Care ; Humans ; Public Health ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Public health emergencies require rapid responses from experts. Differing viewpoints are common in science, however, "mixed messaging" of varied perspectives can undermine credibility of experts; reduce trust in guidance; and act as a barrier to changing public health behaviours. Collation of a unified voice for effective knowledge creation and translation can be challenging. This work aimed to create a method for rapid psychologically-informed expert guidance during the COVID-19 response.

METHOD: TRICE (Template for Rapid Iterative Consensus of Experts) brings structure, peer-review and consensus to the rapid generation of expert advice. It was developed and trialled with 15 core members of the British Psychological Society COVID-19 Behavioural Science and Disease Prevention Taskforce.

RESULTS: Using TRICE; we have produced 18 peer-reviewed COVID-19 guidance documents; based on rapid systematic reviews; co-created by experts in behavioural science and public health; taking 4-156 days to produce; with approximately 18 experts and a median of 7 drafts per output. We provide worked-examples and key considerations; including a shared ethos and theoretical/methodological framework; in this case; the Behaviour Change Wheel and COM-B.

CONCLUSION: TRICE extends existing consensus methodologies and has supported public health collaboration; co-creation of guidance and translation of behavioural science to practice through explicit processes in generating expert advice for public health emergencies.},
}

*COVID-19
Delivery of Health Care
Humans
Public Health
SARS-CoV-2

@article {pmid34569766,
year = {2021},
author = {Jáuregui Leyes, P and Gaete, L and Ponczosznik, MD and Renzi, G and Labriola, A and Testa, N and Elena Palla, M and Blanco, M and Pochetti, J and Alfonso, J and Cavalotti, A and Esper, V and D'Artagnan, NG and Stier, V and Sáenz Tejeira, MM and Bosaleh, MJ and Prieto, MG and Lukin, A},
title = {[Consensus about Health constance for children and adolescents in order to develop phisical activities and sports. Update 2021].},
journal = {Archivos argentinos de pediatria},
volume = {119},
number = {5},
pages = {S212-S221},
doi = {10.5546/aap.2021.S212},
pmid = {34569766},
issn = {1668-3501},
mesh = {Adolescent ; Adult ; *COVID-19 ; Child ; Exercise ; Humans ; SARS-CoV-2 ; *Sports ; },
abstract = {This document is the update of the Consensus published by SAP in 2014, so that no child nor adolescent is excluded from their right to health and physical activity. The periodic medical control and the school physical education are fundamental tools. As a result, of the SARS-CoV-2 pandemic, sports practice decreased dramatically. Recommendations are formulated that serve as a reference to pediatricians, members of health care teams, educational institutions, and sports at the local, regional, and national level in the preparation of the health certificate for a child or adolescent who will participate in physical or sports activities. The pediatrician will evaluate the child or adolescent knowing that to carry out a healthy life, must perform physical activities with moderate or vigorous intensity. The health certificate implies a shared responsibility between the child or adolescent and/or the responsible adult, the doctor, the physical education teachers and/or the coaches in charge.},
}

Adolescent
Adult
*COVID-19
Child
Exercise
Humans
SARS-CoV-2
*Sports

@article {pmid34548380,
year = {2021},
author = {Schell, CO and Khalid, K and Wharton-Smith, A and Oliwa, J and Sawe, HR and Roy, N and Sanga, A and Marshall, JC and Rylance, J and Hanson, C and Kayambankadzanja, RK and Wallis, LA and Jirwe, M and Baker, T and , and , },
title = {Essential Emergency and Critical Care: a consensus among global clinical experts.},
journal = {BMJ global health},
volume = {6},
number = {9},
pages = {},
pmid = {34548380},
issn = {2059-7908},
support = {K23 AI144029/AI/NIAID NIH HHS/United States ; K23 GM141463/GM/NIGMS NIH HHS/United States ; },
mesh = {*COVID-19 ; Critical Care ; *Emergency Medical Services ; Humans ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Globally, critical illness results in millions of deaths every year. Although many of these deaths are potentially preventable, the basic, life-saving care of critically ill patients are often overlooked in health systems. Essential Emergency and Critical Care (EECC) has been devised as the care that should be provided to all critically ill patients in all hospitals in the world. EECC includes the effective care of low cost and low complexity for the identification and treatment of critically ill patients across all medical specialties. This study aimed to specify the content of EECC and additionally, given the surge of critical illness in the ongoing pandemic, the essential diagnosis-specific care for critically ill patients with COVID-19.

METHODS: In a Delphi process, consensus (>90% agreement) was sought from a diverse panel of global clinical experts. The panel iteratively rated proposed treatments and actions based on previous guidelines and the WHO/ICRC's Basic Emergency Care. The output from the Delphi was adapted iteratively with specialist reviewers into a coherent and feasible package of clinical processes plus a list of hospital readiness requirements.

RESULTS: The 269 experts in the Delphi panel had clinical experience in different acute medical specialties from 59 countries and from all resource settings. The agreed EECC package contains 40 clinical processes and 67 requirements, plus additions specific for COVID-19.

CONCLUSION: The study has specified the content of care that should be provided to all critically ill patients. Implementing EECC could be an effective strategy for policy makers to reduce preventable deaths worldwide.},
}

*COVID-19
Critical Care
*Emergency Medical Services
Humans
SARS-CoV-2

@article {pmid34346558,
year = {2021},
author = {Herrera, JE and Niehaus, WN and Whiteson, J and Azola, A and Baratta, JM and Fleming, TK and Kim, SY and Naqvi, H and Sampsel, S and Silver, JK and Verduzco-Gutierrez, M and Maley, J and Herman, E and Abramoff, B},
title = {Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients.},
journal = {PM & R : the journal of injury, function, and rehabilitation},
volume = {13},
number = {9},
pages = {1027-1043},
pmid = {34346558},
issn = {1934-1563},
mesh = {*COVID-19 ; Disease Progression ; Fatigue/diagnosis/etiology/therapy ; Humans ; *SARS-CoV-2 ; },
}

*COVID-19
Disease Progression
Fatigue/diagnosis/etiology/therapy
Humans
*SARS-CoV-2

@article {pmid34288294,
year = {2021},
author = {Nevermann, N and Wiering, L and Wu, H and Moroder, P and Brandl, A and Globke, B and Krenzien, F and Raschzok, N and Schöning, W and Lurje, G and Öllinger, R and Schmelzle, M and Pratschke, J and Ritschl, PV},
title = {Transplantation programs facing lack of empirical evidence on SARS-CoV-2 vaccination: A society recommendation consensus update.},
journal = {Transplant infectious disease : an official journal of the Transplantation Society},
volume = {23},
number = {4},
pages = {e13696},
pmid = {34288294},
issn = {1399-3062},
mesh = {*COVID-19 ; *COVID-19 Vaccines ; Humans ; RNA, Viral ; SARS-CoV-2 ; Vaccination ; },
abstract = {BACKGROUND: Since phase III trials for the most prominent vaccines excluded immunocompromised or immunosuppressed patients, data on safety and efficacy of SARS-CoV-2 vaccines for recipients of solid organ transplantations are scarce.

AIMS: Our study offers a synthesis of expert opinions aligned with available data addressing key questions of the clinical management of SARS-CoV-2 vaccinations for transplant patients.

METHOD: An online research was performed retrieving available recommendations by national and international transplantation organizations and state institutions on SARS-CoV2 vaccination management for transplant recipients.

RESULTS: Eleven key statements were identified from recommendations by 18 national and international societies, and consensus for the individual statements was evaluated by means of the Society Recommendation Consensus score. The highest consensus level (SRC A) was found for prioritized access to vaccination for transplant patients despite anticipation of a weakened immune response. All currently authorized vaccines can be considered safe for transplant patients (SRC A). The handling of immunosuppressive medication, the timely management of vaccines, and other aspects were aligned with available expert opinions.

CONCLUSION: Expert consensus can be determined for crucial aspects of the implementation of SARS-CoV-2 vaccination programs. We hereby offer a tool for immediate decision-making until empirical data becomes available.},
}

*COVID-19
*COVID-19 Vaccines
Humans
RNA, Viral
SARS-CoV-2
Vaccination

@article {pmid34281989,
year = {2021},
author = {Guidon, AC and Burton, LB and Chwalisz, BK and Hillis, J and Schaller, TH and Amato, AA and Betof Warner, A and Brastianos, PK and Cho, TA and Clardy, SL and Cohen, JV and Dietrich, J and Dougan, M and Doughty, CT and Dubey, D and Gelfand, JM and Guptill, JT and Johnson, DB and Juel, VC and Kadish, R and Kolb, N and LeBoeuf, NR and Linnoila, J and Mammen, AL and Martinez-Lage, M and Mooradian, MJ and Naidoo, J and Neilan, TG and Reardon, DA and Rubin, KM and Santomasso, BD and Sullivan, RJ and Wang, N and Woodman, K and Zubiri, L and Louv, WC and Reynolds, KL},
title = {Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.},
journal = {Journal for immunotherapy of cancer},
volume = {9},
number = {7},
pages = {},
pmid = {34281989},
issn = {2051-1426},
support = {K24 HL150238/HL/NHLBI NIH HHS/United States ; },
mesh = {Drug-Related Side Effects and Adverse Reactions/*diagnosis ; Humans ; Immune Checkpoint Inhibitors/*adverse effects ; Immunotherapy/*adverse effects ; Nervous System Diseases/chemically induced/*diagnosis/immunology ; Neurologists/statistics & numerical data ; Oncologists/statistics & numerical data ; Patient Care Team/organization & administration/statistics & numerical data ; *Practice Guidelines as Topic ; },
abstract = {Expanding the US Food and Drug Administration-approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%-12% and a high fatality rate relative to other irAEs. Lack of standardized disease definitions and accurate phenotyping leads to syndrome misclassification and impedes development of evidence-based treatments and translational research. The objective of this study was to develop consensus guidance for an approach to irAE-Ns including disease definitions and severity grading. A working group of four neurologists drafted irAE-N consensus guidance and definitions, which were reviewed by the multidisciplinary Neuro irAE Disease Definition Panel including oncologists and irAE experts. A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND/University of California Los Angeles (UCLA) Appropriateness Method with prespecified definitions. 27 panelists from 15 academic medical centers voted on a total of 53 rating scales (6 general guidance, 24 central and 18 peripheral nervous system disease definition components, 3 severity criteria and 2 clinical trial adjudication statements); of these, 77% (41/53) received first round consensus. After revisions, all items received second round consensus. Consensus definitions were achieved for seven core disorders: irMeningitis, irEncephalitis, irDemyelinating disease, irVasculitis, irNeuropathy, irNeuromuscular junction disorders and irMyopathy. For each disorder, six descriptors of diagnostic components are used: disease subtype, diagnostic certainty, severity, autoantibody association, exacerbation of pre-existing disease or de novo presentation, and presence or absence of concurrent irAE(s). These disease definitions standardize irAE-N classification. Diagnostic certainty is not always directly linked to certainty to treat as an irAE-N (ie, one might treat events in the probable or possible category). Given consensus on accuracy and usability from a representative panel group, we anticipate that the definitions will be used broadly across clinical and research settings.},
}

Drug-Related Side Effects and Adverse Reactions/*diagnosis
Humans
Immune Checkpoint Inhibitors/*adverse effects
Immunotherapy/*adverse effects
Nervous System Diseases/chemically induced/*diagnosis/immunology
Neurologists/statistics & numerical data
Oncologists/statistics & numerical data
Patient Care Team/organization & administration/statistics & numerical data
*Practice Guidelines as Topic

@article {pmid34216091,
year = {2021},
author = {McKenney, SE and Wait, JMS and Cooper, VN and Johnson, AM and Wang, J and Leung, AN and Clements, J},
title = {Multi-institution consensus paper for acquisition of portable chest radiographs through glass barriers.},
journal = {Journal of applied clinical medical physics},
volume = {22},
number = {8},
pages = {219-229},
pmid = {34216091},
issn = {1526-9914},
mesh = {*COVID-19 ; Humans ; Phantoms, Imaging ; Radiation Dosage ; Radiography, Thoracic ; SARS-CoV-2 ; },
abstract = {BACKGROUND: To conserve personal protective equipment (PPE) and reduce exposure to potentially infected COVID-19 patients, several Californian facilities independently implemented a method of acquiring portable chest radiographs through glass barriers that was originally developed by the University of Washington.

METHODS: This work quantifies the transmission of radiation through a glass barrier using six radiographic systems at five facilities. Patient entrance air kerma (EAK) and effective dose were estimated both with and without the glass barrier. Beam penetrability and resulting exposure index (EI) and deviation index (DI) were measured and used to adjust the tube current-time product (mAs) for glass barriers. Because of beam hardening, the contrast-to-noise ratio (CNR) was measured with image quality phantoms to ensure diagnostic integrity. Finally, scatter surveys were performed to assess staff radiation exposure both inside and outside the exam room.

RESULTS: The glass barriers attenuated a mean of 61% of the normal X-ray beams. When the mAs was increased to match EI values, there was no discernible degradation of image quality as determined by the CNR. This was corroborated with subjective assessments of image quality by chest radiologists. The glass-hardened beams acted as a filter for low energy X-rays, and some facilities observed slight changes in patient effective doses. There was scattering from both the phantoms and the glass barriers within the room.

CONCLUSIONS: Glass barriers require an approximate 2.5 times increase in beam intensity, with all other technique factors held constant. Further refinements are necessary for increased source-to-image distance and beam quality in order to adequately match EI values. This does not result in a significant increase in the radiation dose delivered to the patient. The use of lead aprons, mobile shields, and increased distance from scattering sources should be employed where practicable in order to keep staff radiation doses as low as reasonably achievable.},
}

*COVID-19
Humans
Phantoms, Imaging
Radiation Dosage
Radiography, Thoracic
SARS-CoV-2

@article {pmid34196063,
year = {2021},
author = {Gurzawska-Comis, K and Becker, K and Brunello, G and Klinge, B},
title = {COVID-19: Review of European recommendations and experts' opinion on dental care. Summary and consensus statements of group 5. The 6th EAO Consensus Conference 2021.},
journal = {Clinical oral implants research},
volume = {32 Suppl 21},
number = {Suppl 21},
pages = {382-388},
pmid = {34196063},
issn = {1600-0501},
mesh = {*COVID-19 ; Dental Care ; Humans ; Pandemics ; SARS-CoV-2 ; },
abstract = {OBJECTIVES: The present work reports the EAO workshop group 5 and consensus plenary discussions and statements based on two reviews summarising European guidelines and experts' opinion on infection control and prevention (ICP) in dentistry during the pandemic.

MATERIAL: Two manuscripts were presented at the 6th EAO Consensus Conference. The first study compared the most recent national guidelines/recommendations of European countries. The second paper was an experts' opinion-based survey on application of ICP regulation during the second wave. The outcome of COVID-19 group discussion was presented to all participants of the consensus to come to an agreement about the consensus statements and clinical recommendation.

RESULTS: The dynamic of the pandemic had an impact on rapidly published and frequently updated national guidelines in Europe. As guidelines were not based on solid evidence, they were supplemented by experts' opinion on ICP in dentistry. The dental care should be guaranteed during the pandemic; however, in case of suspected or confirmed COVID-19 disease, the treatment should be postponed if possible. Remote triage and patient-related measures (i.e., social distancing, hand hygiene and mask wearing) were recommended to be the most efficient to reduce SARS-CoV-2 transmission. The type of personal protective equipment for dental staff should be adequate to the procedure and infection risk.

CONCLUSIONS: Adequate infection control protocols have to be followed by healthcare professionals and patients to minimise the spreading of COVID-19. We foresee the importance of continuously updating the national dental guidelines, considering the evolution of the pandemic and new scientific evidence becoming available.},
}

*COVID-19
Dental Care
Humans
Pandemics
SARS-CoV-2

@article {pmid34040271,
year = {2021},
author = {Pérez Acosta, G and González Romero, D and Santana-Cabrera, L},
title = {[Consensus document on tracheotomy in patients with COVID 19].},
journal = {Medicina intensiva},
volume = {45},
number = {4},
pages = {253-254},
pmid = {34040271},
issn = {2173-5727},
mesh = {*Aerosols/adverse effects ; COVID-19/*prevention & control/transmission ; Equipment Design ; Humans ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; Intubation, Intratracheal/methods ; Practice Guidelines as Topic ; *Protective Devices ; Respiration, Artificial ; *SARS-CoV-2/isolation & purification ; Tracheotomy/*methods ; },
}

*Aerosols/adverse effects
COVID-19/*prevention & control/transmission
Equipment Design
Humans
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
Intubation, Intratracheal/methods
Practice Guidelines as Topic
*Protective Devices
Respiration, Artificial
*SARS-CoV-2/isolation & purification
Tracheotomy/*methods

@article {pmid34022333,
year = {2022},
author = {Fay, FF and Alvarez-Moreno, CA and Bonvehi, PE and Espinoza, CC and Hidalgo, MLH and Marcano-Lozada, M and Perez, CM and Pulchinelli, A and Sáenz-Flor, KV and Condino-Neto, A},
title = {A simplified alternative diagnostic algorithm for SARS-CoV-2 suspected symptomatic patients and confirmed close contacts (asymptomatic): A consensus of Latin American experts.},
journal = {International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases},
volume = {117},
number = {},
pages = {130-136},
pmid = {34022333},
issn = {1878-3511},
mesh = {Algorithms ; *COVID-19/diagnosis ; COVID-19 Testing ; Humans ; Latin America/epidemiology ; *SARS-CoV-2 ; },
abstract = {INTRODUCTION: Latin America accounts for one-quarter of global COVID-19 cases and one-third of deaths. Inequalities in the region lead to barriers to the best use of diagnostic tests during the pandemic. There is a need for simplified guidelines that consider the region's limited health resources, international guidelines, medical literature, and local expertise.

METHODS: Using a modified Delphi method, 9 experts from Latin American countries developed a simplified algorithm for COVID-19 diagnosis on the basis of their answers to 24 questions related to diagnostic settings, and discussion of the literature and their experiences.

RESULTS: The algorithm considers 3 timeframes (≤7 days, 8-13 days, and ≥14 days) and presents diagnostic options for each. SARS-CoV-2 real- time reverse transcription-polymerase chain reaction is the test of choice from day 1 to 14 after symptom onset or close contact, although antigen testing may be used in specific circumstances, from day 5 to 7. Antibody assays may be used for confirmation, usually after day 14; however, if clinical suspicion is very high, but other tests are negative, these assays may be used as an adjunct to decision-making from day 8 to 13.

CONCLUSION: The proposed algorithm aims to support COVID-19 diagnosis decision-making in Latin America.},
}

Algorithms
*COVID-19/diagnosis
COVID-19 Testing
Humans
Latin America/epidemiology
*SARS-CoV-2

@article {pmid33835086,
year = {2021},
author = {Haug, MD and Lekakis, G and Bussi, M and Cerkes, N and Calvert, J and East, C and Gerbault, O and Gubisch, W and Heppt, W and Kamburoglu, H and Most, S and Oranges, CM and Vavrina, J and Rohrich, RJ and Robotti, E},
title = {Rhinosurgery during and after the COVID-19 Pandemic: International Consensus Conference Statement on Preliminary Perioperative Safety Measures.},
journal = {Plastic and reconstructive surgery},
volume = {147},
number = {5},
pages = {1087-1095},
doi = {10.1097/PRS.0000000000007868},
pmid = {33835086},
issn = {1529-4242},
mesh = {Ambulatory Care Facilities/organization & administration/standards ; Ambulatory Surgical Procedures/standards ; COVID-19/epidemiology/*prevention & control/transmission ; Congresses as Topic ; Elective Surgical Procedures/standards ; Humans ; Infection Control/organization & administration/*standards ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; Pandemics/prevention & control ; Preoperative Care/*standards ; Rhinoplasty/*standards ; Surgeons ; Videoconferencing ; },
abstract = {BACKGROUND: The coronavirus disease of 2019 (COVID-19) pandemic has widely affected rhinosurgery, given the high risk of contagion and the elective nature of the aesthetic procedure, generating many questions on how to ensure safety. The Science and Research Committee of the Rhinoplasty Society of Europe aimed at preparing consensus recommendations on safe rhinosurgery in general during the COVID-19 pandemic by appointing an international panel of experts also including delegates of The Rhinoplasty Society.

METHODS: A Zoom meeting was performed with a panel of 14 international leading experts in rhinosurgery. During 3.5 hours, four categories of questions on preoperative safety measures in private practice and outpatient clinics, patient assessment before and during surgery, and legal issues were presented by four chairs and discussed by the expert group. Afterward, the panelists were requested to express an online, electronic vote on each category and question. The panel's recommendations were based on current evidence and expert opinions. The resulting report was circulated in an iterative open e-mail process until consensus was obtained.

RESULTS: Consensus was obtained in several important points on how to safely restart performing rhinosurgery in general. Preliminary recommendations with different levels of agreement were prepared and condensed in a bundle of safety measures.

CONCLUSION: The implementation of the panel's recommendations may improve safety of rhinoplasty by avoiding operating on nondetected COVID-19 patients and minimizing severe acute respiratory syndrome coronavirus 2 virus spread in outpatient clinics and operating rooms.},
}

Ambulatory Care Facilities/organization & administration/standards
Ambulatory Surgical Procedures/standards
COVID-19/epidemiology/*prevention & control/transmission
Congresses as Topic
Elective Surgical Procedures/standards
Humans
Infection Control/organization & administration/*standards
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
Pandemics/prevention & control
Preoperative Care/*standards
Rhinoplasty/*standards
Surgeons
Videoconferencing

@article {pmid33730365,
year = {2021},
author = {Hagemann, J and Onorato, GL and Jutel, M and Akdis, CA and Agache, I and Zuberbier, T and Czarlewski, W and Mullol, J and Bedbrook, A and Bachert, C and Bennoor, KS and Bergmann, KC and Braido, F and Camargos, P and Caraballo, L and Cardona, V and Casale, T and Cecchi, L and Chivato, T and Chu, DK and Cingi, C and Correia-de-Sousa, J and Del Giacco, S and Dokic, D and Dykewicz, M and Ebisawa, M and El-Gamal, Y and Emuzyte, R and Fauquert, JL and Fiocchi, A and Fokkens, WJ and Fonseca, JA and Gemicioglu, B and Gomez, RM and Gotua, M and Haahtela, T and Hamelmann, E and Iinuma, T and Ivancevich, JC and Jassem, E and Kalayci, O and Kardas, P and Khaitov, M and Kuna, P and Kvedariene, V and Larenas-Linnemann, DE and Lipworth, B and Makris, M and Maspero, JF and Miculinic, N and Mihaltan, F and Mohammad, Y and Montefort, S and Morais-Almeida, M and Mösges, R and Naclerio, R and Neffen, H and Niedoszytko, M and O'Hehir, RE and Ohta, K and Okamoto, Y and Okubo, K and Panzner, P and Papadopoulos, NG and Passalacqua, G and Patella, V and Pereira, A and Pfaar, O and Plavec, D and Popov, TA and Prokopakis, EP and Puggioni, F and Raciborski, F and Reijula, J and Regateiro, FS and Reitsma, S and Romano, A and Rosario, N and Rottem, M and Ryan, D and Samolinski, B and Sastre, J and Solé, D and Sova, M and Stellato, C and Suppli-Ulrik, C and Tsiligianni, I and Valero, A and Valiulis, A and Valovirta, E and Vasankari, T and Ventura, MT and Wallace, D and Wang, Y and Williams, S and Yorgancioglu, A and Yusuf, OM and Zernotti, M and Bousquet, J and Klimek, L},
title = {Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA[2] LEN consensus.},
journal = {Allergy},
volume = {76},
number = {8},
pages = {2354-2366},
pmid = {33730365},
issn = {1398-9995},
mesh = {*Asthma ; *COVID-19 ; *Common Cold ; Humans ; *Rhinitis, Allergic/diagnosis ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases.

METHODS: A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis.

RESULTS: Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p < .001).

CONCLUSIONS: This modified Delphi approach enabled the differentiation of upper respiratory symptoms between COVID-19, the common cold and allergic rhinitis. An electronic algorithm will be devised using the questionnaire.},
}

*Asthma
*COVID-19
*Common Cold
Humans
*Rhinitis, Allergic/diagnosis
SARS-CoV-2

@article {pmid33624042,
year = {2021},
author = {Ambrosetti, M and Abreu, A and Cornelissen, V and Hansen, D and Iliou, MC and Kemps, H and Pedretti, RFE and Voller, H and Wilhelm, M and Piepoli, MF and Beccaluva, CG and Beckers, P and Berger, T and Davos, CH and Dendale, P and Doehner, W and Frederix, I and Gaita, D and Gevaert, A and Kouidi, E and Kraenkel, N and Laukkanen, J and Maranta, F and Mazza, A and Mendes, M and Neunhaeuserer, D and Niebauer, J and Pavy, B and Gil, CP and Rauch, B and Sarzi Braga, S and Simonenko, M and Cohen-Solal, A and Sommaruga, M and Venturini, E and Vigorito, C},
title = {Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era.},
journal = {European journal of preventive cardiology},
volume = {28},
number = {5},
pages = {541-557},
pmid = {33624042},
issn = {2047-4881},
mesh = {COVID-19/*epidemiology ; Cardiac Rehabilitation/*methods ; Cardiovascular Diseases/*epidemiology/therapy ; Comorbidity ; Delphi Technique ; Humans ; *Pandemics ; SARS-CoV-2 ; },
abstract = {This Delphi consensus by 28 experts from the European Association of Preventive Cardiology (EAPC) provides initial recommendations on how cardiovascular rehabilitation (CR) facilities should modulate their activities in view of the ongoing coronavirus disease 2019 (COVID-19) pandemic. A total number of 150 statements were selected and graded by Likert scale [from -5 (strongly disagree) to +5 (strongly agree)], starting from six open-ended questions on (i) referral criteria, (ii) optimal timing and setting, (iii) core components, (iv) structure-based metrics, (v) process-based metrics, and (vi) quality indicators. Consensus was reached on 58 (39%) statements, 48 'for' and 10 'against' respectively, mainly in the field of referral, core components, and structure of CR activities, in a comprehensive way suitable for managing cardiac COVID-19 patients. Panelists oriented consensus towards maintaining usual activities on traditional patient groups referred to CR, without significant downgrading of intervention in case of COVID-19 as a comorbidity. Moreover, it has been suggested to consider COVID-19 patients as a referral group to CR per se when the viral disease is complicated by acute cardiovascular (CV) events; in these patients, the potential development of COVID-related CV sequelae, as well as of pulmonary arterial hypertension, needs to be focused. This framework might be used to orient organization and operational of CR programmes during the COVID-19 crisis.},
}

COVID-19/*epidemiology
Cardiac Rehabilitation/*methods
Cardiovascular Diseases/*epidemiology/therapy
Comorbidity
Delphi Technique
Humans
*Pandemics
SARS-CoV-2

@article {pmid33463975,
year = {2021},
author = {Allegra, C and Failla, G and Costanzo, L and Mannello, F and Montella, F and Antignani, PL},
title = {Reasoned therapeutic protocol in outpatients with COVID-19.},
journal = {International angiology : a journal of the International Union of Angiology},
volume = {40},
number = {2},
pages = {170-175},
doi = {10.23736/S0392-9590.21.04556-9},
pmid = {33463975},
issn = {1827-1839},
mesh = {Female ; Humans ; Male ; Age Factors ; *Clinical Protocols ; Comorbidity ; *COVID-19/diagnosis/therapy ; *COVID-19 Drug Treatment ; Hospitalization/trends ; Italy ; *Outpatients ; Risk Reduction Behavior ; SARS-CoV-2/isolation & purification ; },
abstract = {BACKGROUND: Seventy percent of patients affected by SARS-COV-2 disease are asymptomatic or with symptoms that not required Hospitalization. A prodromal period lasting about 5 days can be identified. In this phase a patient with a positive swab for viral RNA may or may not evolve towards the phase of symptomatic disease.

METHODS: In this paper we reviewed the literature related to COVID-19 therapy we propose a reasoned treatment protocols in outpatients according to the age and the comorbidity.

RESULTS: The aim of this study was to reduce the impact of the virus by reducing its ability to attack cells and the inflammatory burden and the prothrombotic effects proposing two therapeutic schemes of proven efficacy according to the age of the patients and the comorbidities.

CONCLUSIONS: We aimed to reduce worsening of clinical status and hospitalization while protecting patients at home.},
}

Female
Humans
Male
Age Factors
*Clinical Protocols
Comorbidity
*COVID-19/diagnosis/therapy
*COVID-19 Drug Treatment
Hospitalization/trends
Italy
*Outpatients
Risk Reduction Behavior
SARS-CoV-2/isolation & purification

@article {pmid33428874,
year = {2021},
author = {Camporota, L and Meadows, C and Ledot, S and Scott, I and Harvey, C and Garcia, M and Vuylsteke, A and , },
title = {Consensus on the referral and admission of patients with severe respiratory failure to the NHS ECMO service.},
journal = {The Lancet. Respiratory medicine},
volume = {9},
number = {2},
pages = {e16-e17},
pmid = {33428874},
issn = {2213-2619},
mesh = {COVID-19/*complications ; England ; Extracorporeal Membrane Oxygenation/*methods ; *Hospitalization ; Humans ; *Referral and Consultation ; Respiratory Insufficiency/etiology/*therapy ; SARS-CoV-2 ; Scotland ; State Medicine ; },
}

COVID-19/*complications
England
Extracorporeal Membrane Oxygenation/*methods
*Hospitalization
Humans
*Referral and Consultation
Respiratory Insufficiency/etiology/*therapy
SARS-CoV-2
Scotland
State Medicine

@article {pmid33314245,
year = {2021},
author = {Crespo-Lessmann, A and Plaza, V and , },
title = {Multidisciplinary consensus on sputum induction biosafety during the COVID-19 pandemic.},
journal = {Allergy},
volume = {76},
number = {8},
pages = {2407-2419},
doi = {10.1111/all.14697},
pmid = {33314245},
issn = {1398-9995},
mesh = {*COVID-19 ; Containment of Biohazards ; Humans ; *Pandemics ; SARS-CoV-2 ; Sputum ; },
abstract = {Sputum induction (SI) is the gold standard approach to the non-invasive study of airway inflammation. The differential count of inflammatory cells for SI allows patients with asthma to be classified according to inflammatory phenotypes and predicted therapeutic responses. Since SI involves the generation of aerosols, there is a need to establish a protocol to ensure biosafety in clinical practice during the current COVID-19 pandemic. The multidisciplinary consensus on SI described in this article was developed by 22 experts in SI from different Spanish hospitals who drew on available scientific evidence in achieving consensuated opinions, compiled by means of an electronic survey. We hope that these unified criteria and recommendations will guide health professionals in implementing SI sampling and processing procedures as safely as possible during the COVID-19 pandemic.},
}

*COVID-19
Containment of Biohazards
Humans
*Pandemics
SARS-CoV-2
Sputum

@article {pmid33307320,
year = {2021},
author = {Kalson, NS and Mathews, JA and Toms, AD and Murray, JRD and , },
title = {Clinical prioritisation of revision knee surgical procedures: BASK working group consensus document.},
journal = {The Knee},
volume = {28},
number = {},
pages = {57-63},
pmid = {33307320},
issn = {1873-5800},
mesh = {Aged ; Arthroplasty, Replacement, Knee/*methods ; COVID-19/*epidemiology ; Comorbidity ; Female ; Humans ; Knee Joint/*surgery ; *Knee Prosthesis ; Male ; Middle Aged ; Osteoarthritis, Knee/epidemiology/*surgery ; Pandemics ; Reoperation ; SARS-CoV-2 ; United Kingdom/epidemiology ; },
abstract = {BACKGROUND: Elective orthopaedic surgery during the Covid-19 pandemic requires careful case prioritisation. We aimed to produce consensus-based guidelines on the prioritisation of revision total knee arthroplasty (TKA) procedures.

METHOD: Twenty-three revision TKA scenarios were assigned priority (NHS England/Royal College of Surgeons scale) by the British Association for Surgery of the Knee (BASK) Revision Knee Working Group (n = 24). Consensus agreement was defined as ≥70% respondents (18/24) giving the same prioritisation. Two voting rounds were undertaken; procedures achieving <70% agreement were given their most commonly assigned priority.

RESULTS: 18/23 procedures achieved ≥70% agreement. Three were P1a (surgery within <24 h); DAIR for sepsis, peri-prosthetic fracture (PPF) fixation and PPF-revision TKA. Three were P1b (<72 h); debridement, antibiotics and implant retention (DAIR) for a stable patient, flap coverage for an open knee, and acute extensor mechanism rupture. Eight were P2 (<4 weeks), including aseptic loosening at risk of collapse, inter-stage patients with poor functioning spacers. Five were P3 (<3 months), including second stage revision for infection, revision for instability with limited mobility. Four were P4 (can wait >3 months) e.g. aseptic loosening.

CONCLUSION: Sepsis and PPF surgery are the most urgent procedures. Although most procedures should be undertaken within one to three months (P2/3), these cases represent a small revision practice volume; P4 cases (e.g. aseptic loosening without risk of collapse) make up most surgeons' caseload. These recommendations are a guideline; patient co-morbidities, Covid-19 pathways, availability of support services and multi-disciplinary team discussion within the regional revision network will dictate prioritisation.},
}

Aged
Arthroplasty, Replacement, Knee/*methods
COVID-19/*epidemiology
Comorbidity
Female
Humans
Knee Joint/*surgery
*Knee Prosthesis
Male
Middle Aged
Osteoarthritis, Knee/epidemiology/*surgery
Pandemics
Reoperation
SARS-CoV-2
United Kingdom/epidemiology

@article {pmid33293151,
year = {2021},
author = {Morici, N and Puoti, M and Zocchi, MT and Brambilla, C and Mangiagalli, A and Savonitto, S},
title = {Home-based COVID 19 management: A consensus document from Italian general medical practitioners and hospital consultants in the Lombardy region (Italy).},
journal = {European journal of internal medicine},
volume = {84},
number = {},
pages = {94-96},
pmid = {33293151},
issn = {1879-0828},
mesh = {COVID-19/*therapy ; Consultants ; General Practitioners ; Home Care Services/*standards ; Hospitals ; Humans ; Italy ; },
}

COVID-19/*therapy
Consultants
General Practitioners
Home Care Services/*standards
Hospitals
Humans
Italy

@article {pmid33232878,
year = {2021},
author = {McCarthy, CE and Fedele, S and Ho, M and Shaw, R},
title = {UK consensus recommendations on the management of oral epithelial dysplasia during COVID-19 pandemic outbreaks.},
journal = {Oral oncology},
volume = {112},
number = {},
pages = {105110},
pmid = {33232878},
issn = {1879-0593},
mesh = {COVID-19/*epidemiology ; Disease Outbreaks ; Humans ; Mouth Neoplasms/*therapy ; Precancerous Conditions/*therapy ; Referral and Consultation ; *SARS-CoV-2 ; },
abstract = {OBJECTIVES: Oral Epithelial Dysplasia (OED) is associated with an increased risk of oral cancer development. The SARS-CoV-2 pandemic is necessitating the suspension or dramatic reduction of face-to-face non-urgent elective services, including OED clinics. Little is known regarding the potential impact of elective services suspension upon the risk of OED progression, and whether alternative strategies (e.g. remote consultations) may be introduced to ensure OED surveillance. The aim of this paper is to provide expert-opinion consensus recommendations for the management of OED during the current and future pandemic outbreaks.

MATERIALS AND METHODS: A working group of nine UK-based senior clinicians and academics in Oral and Maxillofacial Surgery and Oral Medicine was created and twelve consensus statements were developed using a modified-Delphi process. Greater than 80% agreement was considered a consensus.

RESULTS: Consensus was achieved for all twelve statements (89-100% agreement). The group agreed that, during the temporary suspension of elective services associated with COVID-19 pandemic outbreaks, patients with OED can be risk stratified to determine the length of accepted delay in face-to-face consultation. Remote consultations with patient-provided clinical photographs may be a useful way of maintaining a level of surveillance in this group of patients.

CONCLUSIONS: Using an expert working group methodology, we have developed consensus recommendations for the monitoring of individuals with OED during pandemic outbreaks associated with temporary suspension of elective services. This has identified areas of future research and highlighted the need for a stronger evidence base to inform the set-up and delivery of surveillance regimens for patients with OED.},
}

COVID-19/*epidemiology
Disease Outbreaks
Humans
Mouth Neoplasms/*therapy
Precancerous Conditions/*therapy
Referral and Consultation
*SARS-CoV-2

@article {pmid33171570,
year = {2020},
author = {Ting, CK and Chen, CW and Liu, SK and Teng, WN and Chien, CT and Chen, KB and Sun, WZ},
title = {Endotracheal Intubation in Patients With COVID-19 Infection: Expert Panel-Based Consensus Recommendations.},
journal = {Asian journal of anesthesiology},
volume = {58},
number = {2},
pages = {61-63},
doi = {10.6859/aja.202006_58(2).0003},
pmid = {33171570},
issn = {2468-824X},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/*therapy ; Humans ; Intubation, Intratracheal/*methods ; Pandemics ; Pneumonia, Viral/*therapy ; SARS-CoV-2 ; },
}

*Betacoronavirus
COVID-19
Coronavirus Infections/*therapy
Humans
Intubation, Intratracheal/*methods
Pandemics
Pneumonia, Viral/*therapy
SARS-CoV-2

@article {pmid32921586,
year = {2020},
author = {Barrios, V and Cosín-Sales, J and Bravo, M and Escobar, C and Gámez, JM and Huelmos, A and Ortiz Cortés, C and Egocheaga, I and García-Pinilla, JM and Jiménez-Candil, J and López-de-Sá, E and Torres Llergo, J and Obaya, JC and Pallares-Carratalá, V and Sanmartín, M and Vidal-Pérez, R and Cequier, Á},
title = {Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of Cardiology.},
journal = {Revista espanola de cardiologia (English ed.)},
volume = {73},
number = {11},
pages = {910-918},
pmid = {32921586},
issn = {1885-5857},
mesh = {*COVID-19 ; *Cardiologists ; *Cardiology ; Humans ; Referral and Consultation ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has changed how we view our consultations. To reduce the risk of spread in the most vulnerable patients (those with heart disease) and health personnel, most face-to-face consultations have been replaced by telemedicine consultations. Although this change has been rapidly introduced, it will most likely become a permanent feature of clinical practice. Nevertheless, there remain serious doubts about organizational and legal issues, as well as the possibilities for improvement etc. In this consensus document of the Spanish Society of Cardiology, we attempt to provide some keys to improve the quality of care in this new way of working, reviewing the most frequent heart diseases attended in the cardiology outpatient clinic and proposing some minimal conditions for this health care process. These heart diseases are ischemic heart disease, heart failure, and arrhythmias. In these 3 scenarios, we attempt to clarify the basic issues that must be checked during the telephone interview, describe the patients who should attend in person, and identify the criteria to refer patients for follow-up in primary care. This document also describes some improvements that can be introduced in telemedicine consultations to improve patient care.},
}

*COVID-19
*Cardiologists
*Cardiology
Humans
Referral and Consultation
SARS-CoV-2
*Telemedicine

@article {pmid32797464,
year = {2020},
author = {Zierhut, M and de, MDS and Gupta, V and Pavesio, C and Nguyen, QD and Chee, SP and Agarwal, R},
title = {[Evolving Consensus of International Uveitis Study Group, Intraocular Inflammation Society, and Foster Ocular Inflammation Society with Uveitis in the Time of COVID-19 Infection].},
journal = {Klinische Monatsblatter fur Augenheilkunde},
volume = {237},
number = {9},
pages = {1124-1128},
pmid = {32797464},
issn = {1439-3999},
mesh = {Betacoronavirus ; COVID-19 ; *Coronavirus Infections ; Humans ; Inflammation ; *Pandemics ; *Pneumonia, Viral ; SARS-CoV-2 ; Uveitis/*diagnosis ; },
abstract = {This document summarizes the experience of the International Uveitis Study Group (IUSG), the Intraocular Inflammation Society (IOIS) and the Foster Ocular Inflammation Society (FOIS) and can aid as a guide for the treatment of uveitis patients in the era of COVID-19 pandemic.},
}

Betacoronavirus
COVID-19
*Coronavirus Infections
Humans
Inflammation
*Pandemics
*Pneumonia, Viral
SARS-CoV-2
Uveitis/*diagnosis

@article {pmid32738846,
year = {2020},
author = {Chopra, HK and Hiremath, SM and Wander, GS and Kumar, AS and Naik, S},
title = {Consensus on STEMI Management in the Era of COVID-19.},
journal = {The Journal of the Association of Physicians of India},
volume = {68},
number = {8},
pages = {76-81},
pmid = {32738846},
issn = {0004-5772},
mesh = {Betacoronavirus ; COVID-19 ; Coronavirus Infections/*complications ; Humans ; Pandemics ; Pneumonia, Viral/*complications ; SARS-CoV-2 ; ST Elevation Myocardial Infarction/complications/*therapy ; },
}

Betacoronavirus
COVID-19
Coronavirus Infections/*complications
Humans
Pandemics
Pneumonia, Viral/*complications
SARS-CoV-2
ST Elevation Myocardial Infarction/complications/*therapy

@article {pmid32716742,
year = {2021},
author = {Cohn, JA and Ghiraldi, EM and Uzzo, RG and Simhan, J},
title = {A Critical Appraisal of the American College of Surgeons Medically Necessary, Time Sensitive Procedures (MeNTS) Scoring System, Urology Consensus Recommendations and Individual Surgeon Case Prioritization for Resumption of Elective Urological Surgery During the COVID-19 Pandemic.},
journal = {The Journal of urology},
volume = {205},
number = {1},
pages = {241-247},
doi = {10.1097/JU.0000000000001315},
pmid = {32716742},
issn = {1527-3792},
mesh = {Adult ; Aged ; COVID-19/epidemiology/*prevention & control/transmission/virology ; Clinical Decision-Making ; Communicable Disease Control/standards ; Elective Surgical Procedures/*standards ; Female ; Humans ; Male ; Middle Aged ; Pandemics/prevention & control ; Patient Selection ; Risk Assessment/methods/standards ; SARS-CoV-2/pathogenicity ; Time Factors ; Triage/standards ; United States/epidemiology ; Urologic Diseases/*surgery ; Urologic Surgical Procedures/*standards ; Urology/*standards ; Young Adult ; },
abstract = {PURPOSE: Resumption of elective urology cases postponed due to the COVID-19 pandemic requires a systematic approach to case prioritization, which may be based on detailed cross-specialty questionnaires, specialty specific published expert opinion or by individual (operating) surgeon review. We evaluated whether each of these systems effectively stratifies cases and for agreement between approaches in order to inform departmental policy.

MATERIALS AND METHODS: We evaluated triage of elective cases postponed within our department due to the COVID-19 pandemic (March 9, 2020 to May 22, 2020) using questionnaire based surgical prioritization (American College of Surgeons Medically Necessary, Time Sensitive Procedures [MeNTS] instrument), consensus/expert opinion based surgical prioritization (based on published urological recommendations) and individual surgeon based surgical prioritization scoring (developed and managed within our department). Lower scores represented greater urgency. MeNTS scores were compared across consensus/expert opinion based surgical prioritization and individual surgeon based surgical prioritization scores.

RESULTS: A total of 204 cases were evaluated. Median MeNTS score was 50 (IQR 44, 55), and mean consensus/expert opinion based surgical prioritization and individual surgeon based surgical prioritization scores were 2.6±0.6 and 2.2±0.8, respectively. Median MeNTS scores were 52 (46.5, 57.5), 50 (44.5, 54.5) and 48 (43.5, 54) for individual surgeon based surgical prioritization priority 1, 2 and 3 cases (p=0.129), and 55 (51.5, 57), 47.5 (42, 56) and 49 (44, 54) for consensus/expert opinion based surgical prioritization priority scores 1, 2, and 3 (p=0.002). There was none to slight agreement between consensus/expert opinion based surgical prioritization and individual surgeon based surgical prioritization scores (Kappa 0.131, p=0.002).

CONCLUSIONS: Questionnaire based, expert opinion based and individual surgeon based approaches to case prioritization result in significantly different case prioritization. Questionnaire based surgical prioritization did not meaningfully stratify urological cases, and consensus/expert opinion based surgical prioritization and individual surgeon based surgical prioritization frequently disagreed. The strengths and weaknesses of each of these systems should be considered in future disaster planning scenarios.},
}

Adult
Aged
COVID-19/epidemiology/*prevention & control/transmission/virology
Clinical Decision-Making
Communicable Disease Control/standards
Elective Surgical Procedures/*standards
Female
Humans
Male
Middle Aged
Pandemics/prevention & control
Patient Selection
Risk Assessment/methods/standards
SARS-CoV-2/pathogenicity
Time Factors
Triage/standards
United States/epidemiology
Urologic Diseases/*surgery
Urologic Surgical Procedures/*standards
Urology/*standards
Young Adult

@article {pmid32702940,
year = {2020},
author = {Buda, N and Andruszkiewicz, P and Czuczwar, M and Gola, W and Kosiak, W and Nowakowski, P and Sporysz, K},
title = {Consensus of the Study Group for Point-of-Care Lung Ultrasound in the intensive care management of COVID-19 patients.},
journal = {Anaesthesiology intensive therapy},
volume = {52},
number = {2},
pages = {83-90},
pmid = {32702940},
issn = {1731-2531},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/*diagnostic imaging/therapy ; *Critical Care ; Humans ; Lung/*diagnostic imaging ; Pandemics ; Pneumonia, Viral/*diagnostic imaging/therapy ; *Point-of-Care Systems ; Respiration, Artificial ; SARS-CoV-2 ; Ultrasonography/*methods ; },
abstract = {Respiratory failure is a dominating medical issue in the severe course of COVID-19. Both at the stage of diagnostics prior to admission to the intensive care unit and during the monitoring of lesion evolution, diagnostic imaging techniques may significantly influence clinical decisions. Although computed tomography remains the gold standard for diagnosing lung diseases, its usefulness for infected, critically ill patients has been largely limited during the pandemic. Reports from those countries in which the healthcare systems were most seriously overloaded with patients with COVID-19-induced pneumonia stress the key role of point-of-care lung ultrasound performed by clinicians first during preliminary diagnostics and then while monitoring disease dynamics. This consensus, worked out by an interdisciplinary team of specialists forming the Study Group for Point-of-Care Lung Ultrasound in the Intensive Care Management of COVID-19 Patients, presents a broad spectrum of aspects regarding the analysed issue. Its concise form is meant to serve clinicians who perform ultrasound as a straightforward and informative guide.},
}

*Betacoronavirus
COVID-19
Coronavirus Infections/*diagnostic imaging/therapy
*Critical Care
Humans
Lung/*diagnostic imaging
Pandemics
Pneumonia, Viral/*diagnostic imaging/therapy
*Point-of-Care Systems
Respiration, Artificial
SARS-CoV-2
Ultrasonography/*methods

@article {pmid32692016,
year = {2020},
author = {Hernández-Tejedor, A and Delgado Sánchez, R},
title = {Consensus on interhospital transfers during the COVID-19 pandemic.},
journal = {Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias},
volume = {32},
number = {4},
pages = {301-302},
pmid = {32692016},
issn = {2386-5857},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/*epidemiology/therapy ; *Guideline Adherence ; Humans ; Pandemics ; Pneumonia, Viral/*epidemiology/therapy ; SARS-CoV-2 ; *Transportation of Patients ; },
}

*Betacoronavirus
COVID-19
Coronavirus Infections/*epidemiology/therapy
*Guideline Adherence
Humans
Pandemics
Pneumonia, Viral/*epidemiology/therapy
SARS-CoV-2
*Transportation of Patients

@article {pmid32683406,
year = {2020},
author = {Alotaibi, F and Althani, Z and Aljaafari, D and Tayeb, HO and Baarmah, D and Aljalal, N and Muthaffar, O and Alqulaiti, K and Alhameed, M and Ali, B and Qureshi, S and Albaradie, R},
title = {Saudi Epilepsy Society consensus on epilepsy management during the COVID-19 Pandemic.},
journal = {Neurosciences (Riyadh, Saudi Arabia)},
volume = {25},
number = {3},
pages = {222-225},
pmid = {32683406},
issn = {1319-6138},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/*complications/drug therapy ; *Disease Management ; Drug Interactions ; Epilepsy/*complications/*drug therapy/epidemiology ; Humans ; Pandemics ; Pneumonia, Viral/*complications/drug therapy ; SARS-CoV-2 ; Saudi Arabia/epidemiology ; *Societies, Medical ; },
}

*Betacoronavirus
COVID-19
Coronavirus Infections/*complications/drug therapy
*Disease Management
Drug Interactions
Epilepsy/*complications/*drug therapy/epidemiology
Humans
Pandemics
Pneumonia, Viral/*complications/drug therapy
SARS-CoV-2
Saudi Arabia/epidemiology
*Societies, Medical

@article {pmid32682031,
year = {2020},
author = {Murrell, DF and Lucky, AW and Salas-Alanis, JC and Woodley, DT and Palisson, F and Natsuga, K and Nikolic, M and Ramirez-Quizon, M and Paller, AS and Lara-Corrales, I and Barzegar, MA and Sprecher, E and Has, C and Laimer, M and Bruckner, AL and Bilgic, A and Nanda, A and Purvis, D and Hovnanian, A and Murat-Sušić, S and Bauer, J and Kern, JS and Bodemer, C and Martin, LK and Mellerio, J and Kowaleski, C and Robertson, SJ and Bruckner-Tuderman, L and Pope, E and Marinkovich, MP and Tang, JY and Su, J and Uitto, J and Eichenfield, LF and Teng, J and Aan Koh, MJ and Lee, SE and Khuu, P and Rishel, HI and Sommerlund, M and Wiss, K and Hsu, CK and Chiu, TW and Martinez, AE},
title = {Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts.},
journal = {Journal of the American Academy of Dermatology},
volume = {83},
number = {4},
pages = {1222-1224},
pmid = {32682031},
issn = {1097-6787},
mesh = {Betacoronavirus/*immunology ; COVID-19 ; Coronavirus Infections/epidemiology/immunology/*prevention & control/transmission ; Epidermolysis Bullosa/immunology/*therapy ; Humans ; Interdisciplinary Communication ; Pandemics/*prevention & control ; Patient Care Team/*standards ; Pneumonia, Viral/epidemiology/immunology/*prevention & control/transmission ; Practice Guidelines as Topic ; SARS-CoV-2 ; },
}

Betacoronavirus/*immunology
COVID-19
Coronavirus Infections/epidemiology/immunology/*prevention & control/transmission
Epidermolysis Bullosa/immunology/*therapy
Humans
Interdisciplinary Communication
Pandemics/*prevention & control
Patient Care Team/*standards
Pneumonia, Viral/epidemiology/immunology/*prevention & control/transmission
Practice Guidelines as Topic
SARS-CoV-2

@article {pmid32680593,
year = {2021},
author = {Pérez Acosta, G and González Romero, D and Santana-Cabrera, L},
title = {Consensus document on tracheotomy in patients with COVID 19.},
journal = {Medicina intensiva},
volume = {45},
number = {4},
pages = {253-254},
pmid = {32680593},
issn = {2173-5727},
mesh = {COVID-19/prevention & control/*transmission ; Equipment Design ; Humans ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; Respiration, Artificial/*adverse effects ; Tracheotomy/adverse effects/*instrumentation/methods ; },
}

COVID-19/prevention & control/*transmission
Equipment Design
Humans
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
Respiration, Artificial/*adverse effects
Tracheotomy/adverse effects/*instrumentation/methods

@article {pmid32621065,
year = {2020},
author = {Wiedemann, D and Bernardi, MH and Distelmaier, K and Goliasch, G and Hengstenberg, C and Hermann, A and Holzer, M and Hoetzenecker, K and Klepetko, W and Lang, G and Lassnigg, A and Laufer, G and Magnet, IAM and Markstaller, K and Röggla, M and Rössler, B and Schellongowski, P and Simon, P and Tschernko, E and Ullrich, R and Zimpfer, D and Staudinger, T and , },
title = {Recommendations for extracorporeal membrane oxygenation (ECMO) in COVID-19 patients : Consensus paper of the Medical University of Vienna.},
journal = {Wiener klinische Wochenschrift},
volume = {132},
number = {21-22},
pages = {671-676},
pmid = {32621065},
issn = {1613-7671},
mesh = {Aged ; *Betacoronavirus ; COVID-19 ; Child ; *Coronavirus Infections ; *Extracorporeal Membrane Oxygenation ; Humans ; *Pandemics ; *Pneumonia, Viral ; SARS-CoV-2 ; },
abstract = {The pandemic from the SARS-CoV‑2 virus is currently challenging healthcare systems all over the world. Maintaining appropriate staffing and resources in healthcare facilities is essential to guarantee a safe working environment for healthcare personnel and safe patient care. Extracorporeal membrane oxygenation (ECMO) represents a valuable therapeutic option in patients with severe heart or lung failure. Although only a limited proportion of COVID-19 patients develop respiratory or circulatory failure that is refractory to conventional treatment, it is of utmost importance to clearly define criteria for the use of ECMO in this steadily growing patient population. The ECMO working group of the Medical University of Vienna has established the following recommendations for ECMO support in COVID-19 patients.},
}

Aged
*Betacoronavirus
COVID-19
Child
*Coronavirus Infections
*Extracorporeal Membrane Oxygenation
Humans
*Pandemics
*Pneumonia, Viral
SARS-CoV-2

@article {pmid32595225,
year = {2020},
author = {Hamilton, B and Anderson, L and Anglem, N and Armstrong, S and Baker, S and Beable, S and Burt, P and Coleman, L and Doughty, R and Edwards, T and Exeter, D and Fulcher, M and Kara, S and Mayhew, J and Mayhew, S and Milne, C and O'Neill, B and Osborne, H and Parnell, M and Pearson, J and Rasmussen, K and Scheffer, J and Swan, M and Thomas, M and Gerrard, D},
title = {Medical considerations for supporting elite athletes during the post-peak phase of the New Zealand COVID-19 pandemic: a New Zealand sporting code consensus.},
journal = {The New Zealand medical journal},
volume = {133},
number = {1517},
pages = {107-116},
pmid = {32595225},
issn = {1175-8716},
mesh = {Athletes/psychology ; *Betacoronavirus ; COVID-19 ; Coronavirus Infections/diagnosis/epidemiology/*prevention & control ; Humans ; New Zealand/epidemiology ; Pandemics/*prevention & control ; Pneumonia, Viral/diagnosis/epidemiology/*prevention & control ; SARS-CoV-2 ; *Sports ; },
}

Athletes/psychology
*Betacoronavirus
COVID-19
Coronavirus Infections/diagnosis/epidemiology/*prevention & control
Humans
New Zealand/epidemiology
Pandemics/*prevention & control
Pneumonia, Viral/diagnosis/epidemiology/*prevention & control
SARS-CoV-2
*Sports

@article {pmid32558523,
year = {2021},
author = {Rayegani, SM and Raeissadat, SA and Fakharian, A and Babaee, M and Nezamabadi, M and Boland Nazar, NS and Angooti, L},
title = {Role of rehabilitation medicine in the COVID-19 pandemic: an Iranian consensus.},
journal = {European journal of physical and rehabilitation medicine},
volume = {57},
number = {2},
pages = {309-310},
doi = {10.23736/S1973-9087.20.06366-2},
pmid = {32558523},
issn = {1973-9095},
mesh = {COVID-19/epidemiology/*rehabilitation ; Humans ; Iran/epidemiology ; *Pandemics ; Physical and Rehabilitation Medicine/*methods ; SARS-CoV-2 ; },
}

COVID-19/epidemiology/*rehabilitation
Humans
Iran/epidemiology
*Pandemics
Physical and Rehabilitation Medicine/*methods
SARS-CoV-2

@article {pmid32495231,
year = {2020},
author = {Vistoli, F and Furian, L and Maggiore, U and Caldara, R and Cantaluppi, V and Ferraresso, M and Zaza, G and Cardillo, M and Biancofiore, G and Menichetti, F and Russo, A and Turillazzi, E and Di Paolo, M and Grandaliano, G and Boggi, U and , and , },
title = {COVID-19 and kidney transplantation: an Italian Survey and Consensus.},
journal = {Journal of nephrology},
volume = {33},
number = {4},
pages = {667-680},
pmid = {32495231},
issn = {1724-6059},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/drug therapy/*epidemiology ; Humans ; *Kidney Transplantation ; Living Donors ; Pandemics ; Pneumonia, Viral/drug therapy/*epidemiology ; SARS-CoV-2 ; },
abstract = {Italy was the first Western country to face the COVID-19 pandemic. Here we report the results of a national survey on kidney transplantation activity in February and March 2020, and the results of a three-round Delphi consensus promoted by four scientific societies: the Italian Society of Organ Transplantation, the Italian Society of Nephrology, the Italian Society of Anesthesia and Intensive Care, and the Italian Group on Antimicrobial Stewardship. All 41 Italian transplant centers were invited to express their opinion in the Delphi rounds along with a group of seven experts. The survey revealed that, starting from March 2020, there was a decline in kidney transplantation activity in Italy, especially for living-related transplants. Overall, 60 recipients tested positive for SARS-CoV2 infection, 57 required hospitalization, 17 were admitted to the ICU, and 11 died. The online consensus had high response rates at each round (95.8%, 95.8%, and 89.5%, respectively). Eventually, 27 of 31 proposed statements were approved (87.1%), 12 at the first or second round (38.7%), and 3 at the third (9.7%). Based on the Italian experience, we discuss the reasons for the changes in kidney transplantation activity during the COVID-19 pandemic in Western countries. We also provide working recommendations for the organization and management of kidney transplantation under these conditions.},
}

*Betacoronavirus
COVID-19
Coronavirus Infections/drug therapy/*epidemiology
Humans
*Kidney Transplantation
Living Donors
Pandemics
Pneumonia, Viral/drug therapy/*epidemiology
SARS-CoV-2

@article {pmid32447721,
year = {2020},
author = {, and Lau, G and Sharma, M},
title = {Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations.},
journal = {Hepatology international},
volume = {14},
number = {4},
pages = {415-428},
pmid = {32447721},
issn = {1936-0541},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications/epidemiology/*therapy ; Humans ; Liver Diseases/etiology/*therapy ; *Liver Transplantation ; Pandemics ; Patient Selection ; Pneumonia, Viral/complications/epidemiology/*therapy ; Practice Guidelines as Topic ; Practice Patterns, Physicians' ; SARS-CoV-2 ; },
abstract = {BACKGROUND: Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide.

AIMS: In order to enhance scientific information interflow in the arena of liver diseases in Asia-Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials.

METHODS: A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia-Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials.

CONCLUSIONS: This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal.},
}

*Betacoronavirus
COVID-19
Coronavirus Infections/complications/epidemiology/*therapy
Humans
Liver Diseases/etiology/*therapy
*Liver Transplantation
Pandemics
Patient Selection
Pneumonia, Viral/complications/epidemiology/*therapy
Practice Guidelines as Topic
Practice Patterns, Physicians'
SARS-CoV-2

@article {pmid32426220,
year = {2020},
author = {Parsi, K and van Rij, AM and Meissner, MH and Davies, AH and De Maeseneer, M and Gloviczki, P and Benson, S and Bottini, O and Manuel Canata, V and Dinnen, P and Gasparis, A and Gianesini, S and Huber, D and Jenkins, D and Lal, BK and Kabnick, L and Lim, A and Marston, W and Granados, AM and Morrison, N and Nicolaides, A and Paraskevas, P and Patel, M and Roberts, S and Rogan, C and Schul, MW and Komlos, P and Stirling, A and Thibault, S and Varghese, R and Welch, HJ and Wittens, CHA},
title = {Triage of patients with venous and lymphatic diseases during the COVID-19 pandemic - The Venous and Lymphatic Triage and Acuity Scale (VELTAS):: A consensus document of the International Union of Phlebology (UIP), Australasian College of Phlebology (ACP), American Vein and Lymphatic Society (AVLS), American Venous Forum (AVF), European College of Phlebology (ECoP), European Venous Forum (EVF), Interventional Radiology Society of Australasia (IRSA), Latin American Venous Forum, Pan-American Society of Phlebology and Lymphology and the Venous Association of India (VAI).},
journal = {Journal of vascular surgery. Venous and lymphatic disorders},
volume = {8},
number = {5},
pages = {706-710},
pmid = {32426220},
issn = {2213-3348},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/diagnosis/*epidemiology/prevention & control ; Humans ; International Cooperation ; Lymphatic Diseases/diagnosis/*therapy ; Pandemics/prevention & control ; Patient Selection ; Pneumonia, Viral/diagnosis/*epidemiology/prevention & control ; Reproducibility of Results ; SARS-CoV-2 ; Severity of Illness Index ; Societies, Medical ; Triage/*organization & administration ; Vascular Diseases/diagnosis/*therapy ; Vascular Surgical Procedures ; *Veins ; },
abstract = {The coronavirus disease 2019 (COVID-19) global pandemic has resulted in diversion of healthcare resources to the management of patients infected with SARS-CoV-2 virus. Elective interventions and surgical procedures in most countries have been postponed and operating room resources have been diverted to manage the pandemic. The Venous and Lymphatic Triage and Acuity Scale was developed to provide an international standard to rationalise and harmonise the management of patients with venous and lymphatic disorders or vascular anomalies. Triage urgency was determined based on clinical assessment of urgency with which a patient would require medical treatment or surgical intervention. Clinical conditions were classified into six categories of: (1) venous thromboembolism (VTE), (2) chronic venous disease, (3) vascular anomalies, (4) venous trauma, (5) venous compression and (6) lymphatic disease. Triage urgency was categorised into four groups and individual conditions were allocated to each class of triage. These included (1) medical emergencies (requiring immediate attendance), example massive pulmonary embolism; (2) urgent (to be seen as soon as possible), example deep vein thrombosis; (3) semiurgent (to be attended to within 30-90 days), example highly symptomatic chronic venous disease, and (4) discretionary/nonurgent- (to be seen within 6-12 months), example chronic lymphoedema. Venous and Lymphatic Triage and Acuity Scale aims to standardise the triage of patients with venous and lymphatic disease or vascular anomalies by providing an international consensus-based classification of clinical categories and triage urgency. The scale may be used during pandemics such as the current COVID-19 crisis but may also be used as a general framework to classify urgency of the listed conditions.},
}

*Betacoronavirus
COVID-19
Coronavirus Infections/diagnosis/*epidemiology/prevention & control
Humans
International Cooperation
Lymphatic Diseases/diagnosis/*therapy
Pandemics/prevention & control
Patient Selection
Pneumonia, Viral/diagnosis/*epidemiology/prevention & control
Reproducibility of Results
SARS-CoV-2
Severity of Illness Index
Societies, Medical
Triage/*organization & administration
Vascular Diseases/diagnosis/*therapy
Vascular Surgical Procedures
*Veins

@article {pmid32422427,
year = {2020},
author = {Király, O and Potenza, MN and Stein, DJ and King, DL and Hodgins, DC and Saunders, JB and Griffiths, MD and Gjoneska, B and Billieux, J and Brand, M and Abbott, MW and Chamberlain, SR and Corazza, O and Burkauskas, J and Sales, CMD and Montag, C and Lochner, C and Grünblatt, E and Wegmann, E and Martinotti, G and Lee, HK and Rumpf, HJ and Castro-Calvo, J and Rahimi-Movaghar, A and Higuchi, S and Menchon, JM and Zohar, J and Pellegrini, L and Walitza, S and Fineberg, NA and Demetrovics, Z},
title = {Preventing problematic internet use during the COVID-19 pandemic: Consensus guidance.},
journal = {Comprehensive psychiatry},
volume = {100},
number = {},
pages = {152180},
pmid = {32422427},
issn = {1532-8384},
support = {/WT_/Wellcome Trust/United Kingdom ; UL1 TR001863/TR/NCATS NIH HHS/United States ; },
mesh = {*Adaptation, Psychological ; Anxiety/*psychology ; Anxiety Disorders ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/epidemiology/*psychology ; Depression/*psychology ; Humans ; Internet/*statistics & numerical data ; Pandemics ; Pneumonia, Viral/epidemiology/*psychology ; SARS-CoV-2 ; Video Games ; },
abstract = {As a response to the COVID-19 pandemic, many governments have introduced steps such as spatial distancing and "staying at home" to curb its spread and impact. The fear resulting from the disease, the 'lockdown' situation, high levels of uncertainty regarding the future, and financial insecurity raise the level of stress, anxiety, and depression experienced by people all around the world. Psychoactive substances and other reinforcing behaviors (e.g., gambling, video gaming, watching pornography) are often used to reduce stress and anxiety and/or to alleviate depressed mood. The tendency to use such substances and engage in such behaviors in an excessive manner as putative coping strategies in crises like the COVID-19 pandemic is considerable. Moreover, the importance of information and communications technology (ICT) is even higher in the present crisis than usual. ICT has been crucial in keeping parts of the economy going, allowing large groups of people to work and study from home, enhancing social connectedness, providing greatly needed entertainment, etc. Although for the vast majority ICT use is adaptive and should not be pathologized, a subgroup of vulnerable individuals are at risk of developing problematic usage patterns. The present consensus guidance discusses these risks and makes some practical recommendations that may help diminish them.},
}

*Adaptation, Psychological
Anxiety/*psychology
Anxiety Disorders
Betacoronavirus
COVID-19
Coronavirus Infections/epidemiology/*psychology
Depression/*psychology
Humans
Internet/*statistics & numerical data
Pandemics
Pneumonia, Viral/epidemiology/*psychology
SARS-CoV-2
Video Games

@article {pmid32406873,
year = {2020},
author = {Aktoz, M and Altay, H and Aslanger, E and Atalar, E and Atar, İ and Aytekin, V and Baykan, AO and Barçın, C and Barış, N and Boyacı, A and Çavuşoğlu, Y and Çelik, A and Çinier, G and Değertekin, M and Demircan, S and Ergönül, Ö and Ertürk, M and Erol, MK and Görenek, B and Gürsoy, MO and Hünük, B and Kahveci, G and Karabay, CY and Karaca, I and Kayıkçıoğlu, M and Keskin, M and Kılıç, T and KılıçkıranAvcı, B and Kırma, C and Kocabaş, U and Kocakaya, D and Küçükoğlu, S and Mutlu, B and Nalbantgil, S and Okuyan, E and Okyay, K and KaptanÖzen, D and Özgül, S and Özpelit, E and Pirat, B and Sert, S and Sinan, ÜY and Şener, YZ and Tatlı, E and Tekkeşin, Aİ and Tutar, E and Ural, D and Yıldırımtürk, Ö and Yıldızeli, B},
title = {[Turkish Cardiology Association Consensus Report: COVID-19 Pandemic and Cardiovascular Diseases (May 13, 2020)].},
journal = {Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir},
volume = {48},
number = {Suppl 1},
pages = {1-87},
doi = {10.5543/tkda.2020.36713},
pmid = {32406873},
issn = {1308-4488},
mesh = {Betacoronavirus ; COVID-19 ; Cardiology/standards ; *Cardiovascular Diseases/complications/therapy ; *Coronavirus Infections/complications/epidemiology ; Humans ; *Pandemics ; *Pneumonia, Viral/complications/epidemiology ; Practice Guidelines as Topic ; SARS-CoV-2 ; },
abstract = {In December 2019, in the city of Wuhan, in the Hubei province of China, treatment-resistant cases of pneumonia emerged and spread rapidly for reasons unknown. A new strain of coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was identified and caused the first pandemic of the 21st century. The virus was officially detected in our country on March 11, 2020, and the number of cases increased rapidly; the virus was isolated in 670 patients within 10 days. The rapid increase in the number of patients has required our physicians to learn to protect both the public and themselves when treating patients with this highly infectious disease. The group most affected by the outbreak and with the highest mortality rate is elderly patients with known cardiovascular disease. Therefore, it is necessary for cardiology specialists to take an active role in combating the epidemic. The aim of this article is to make a brief assessment of current information regarding the management of cardiovascular patients affected by COVID-19 and to provide practical suggestions to cardiology specialists about problems and questions they have frequently encountered.},
}

Betacoronavirus
COVID-19
Cardiology/standards
*Cardiovascular Diseases/complications/therapy
*Coronavirus Infections/complications/epidemiology
Humans
*Pandemics
*Pneumonia, Viral/complications/epidemiology
Practice Guidelines as Topic
SARS-CoV-2

@article {pmid32401360,
year = {2020},
author = {Weinkove, R and McQuilten, ZK and Adler, J and Agar, MR and Blyth, E and Cheng, AC and Conyers, R and Haeusler, GM and Hardie, C and Jackson, C and Lane, SW and Middlemiss, T and Mollee, P and Mulligan, SP and Ritchie, D and Ruka, M and Solomon, B and Szer, J and Thursky, KA and Wood, EM and Worth, LJ and Yong, MK and Slavin, MA and Teh, BW},
title = {Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.},
journal = {The Medical journal of Australia},
volume = {212},
number = {10},
pages = {481-489},
pmid = {32401360},
issn = {1326-5377},
mesh = {Australia ; *Betacoronavirus ; COVID-19 ; Coronavirus Infections/*complications/virology ; Hematologic Diseases/virology ; Hematology/*standards ; Humans ; Medical Oncology/*standards ; Neoplasms/virology ; New Zealand ; Pandemics ; Pneumonia, Viral/*complications/virology ; *Practice Guidelines as Topic ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic.

MAIN RECOMMENDATIONS: During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning.

This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence.

ENDORSED BY: Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia.},
}

Australia
*Betacoronavirus
COVID-19
Coronavirus Infections/*complications/virology
Hematologic Diseases/virology
Hematology/*standards
Humans
Medical Oncology/*standards
Neoplasms/virology
New Zealand
Pandemics
Pneumonia, Viral/*complications/virology
*Practice Guidelines as Topic
SARS-CoV-2

@article {pmid32376532,
year = {2020},
author = {Bu, J and Chen, M and Cheng, X and Dong, Y and Fang, W and Ge, J and Gong, Y and He, B and Huang, L and Huo, Y and Jia, S and Jiang, J and Li, Y and Li, Z and Liang, C and Liu, X and Liu, Z and Ma, X and Ma, Y and Qian, J and Shen, C and Shen, D and Shen, L and Shi, R and Su, X and Sun, Y and Tang, Y and Wang, J and Wu, Y and Xiang, D and Xu, T and Xu, Y and Yang, Y and Zeng, H and Zhang, C and Zhang, G and Zhang, R and Zhang, S and Zhang, Y and Zhang, Z and Zheng, B and Zhou, N},
title = {[Consensus of Chinese experts on diagnosis and treatment processes of acute myocardial infarction in the context of prevention and control of COVID-19 (first edition)].},
journal = {Nan fang yi ke da xue xue bao = Journal of Southern Medical University},
volume = {40},
number = {2},
pages = {147-151},
doi = {10.12122/j.issn.1673-4254.2020.02.01},
pmid = {32376532},
issn = {1673-4254},
mesh = {Betacoronavirus ; COVID-19 ; *Coronavirus Infections/complications/epidemiology/prevention & control ; Humans ; *Myocardial Infarction/diagnosis/therapy ; *Pandemics/prevention & control ; *Pneumonia, Viral/complications/epidemiology/prevention & control ; Practice Guidelines as Topic ; Remote Consultation ; SARS-CoV-2 ; Thrombolytic Therapy ; Transportation of Patients ; },
abstract = {The SARS-CoV-2 epidemic starting in Wuhan in December, 2019 has spread rapidly throughout the nation. The control measures to contain the epidemic also produced influences on the transport and treatment process of patients with acute myocardial infarction (AMI), and adjustments in the management of the patients need to be made at this particular time. AMI is characterized by an acute onset with potentially fatal consequence, a short optimal treatment window, and frequent complications including respiratory infections and respiratory and circulatory failure, for which active on-site treatment is essential. To standardize the management and facilitate the diagnosis and treatment, we formulated the guidelines for the procedures and strategies for the diagnosis and treatment of AMI, which highlight 5 Key Principles, namely Nearby treatment, Safety protection, Priority of thrombolysis, Transport to designated hospitals, and Remote consultation. For AMI patients, different treatment strategies are selected based on the screening results of SARS-CoV-2, the time window of STEMI onset, and the vital signs of the patients. During this special period, the cardiologists, including the interventional physicians, should be fully aware of the indications and contraindications of thrombolysis. In the transport and treatment of AMI patients, the physicians should strictly observe the indications for patient transport with appropriate protective measurements of the medical staff.},
}

Betacoronavirus
COVID-19
*Coronavirus Infections/complications/epidemiology/prevention & control
Humans
*Myocardial Infarction/diagnosis/therapy
*Pandemics/prevention & control
*Pneumonia, Viral/complications/epidemiology/prevention & control
Practice Guidelines as Topic
Remote Consultation
SARS-CoV-2
Thrombolytic Therapy
Transportation of Patients

@article {pmid32342864,
year = {2020},
author = {Rathod, S and Dubey, A and Bashir, B and Sivananthan, G and Leylek, A and Chowdhury, A and Koul, R},
title = {Bracing for impact with new 4R's in the COVID-19 pandemic - A provincial thoracic radiation oncology consensus.},
journal = {Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology},
volume = {149},
number = {},
pages = {124-127},
pmid = {32342864},
issn = {1879-0887},
mesh = {*Betacoronavirus ; COVID-19 ; Canada ; *Coronavirus Infections ; Humans ; Neoplasms/*radiotherapy ; *Pandemics ; *Pneumonia, Viral ; *Radiation Oncology ; SARS-CoV-2 ; },
abstract = {As COVID-19 pandemic continues to explode, cancer centers worldwide are trying to adapt and are struggling with this constantly changing scenario. Intending to ensure patient safety and deliver quality care, we sought consensus on the preferred thoracic radiation regimen in a Canadian province with 4 new R's of COVID era.},
}

*Betacoronavirus
COVID-19
Canada
*Coronavirus Infections
Humans
Neoplasms/*radiotherapy
*Pandemics
*Pneumonia, Viral
*Radiation Oncology
SARS-CoV-2

@article {pmid32250347,
year = {2020},
author = {Aktoz, M and Altay, H and Aslanger, E and Atalar, E and Aytekin, V and Baykan, AO and Barçın, C and Barış, N and Boyacı, AA and Çavuşoğlu, Y and Çelik, A and Çinier, G and Değertekin, M and Ergönül, Ö and Ertürk, M and Erol, MK and Görenek, B and Gürsoy, MO and Hünük, B and Kahveci, G and Karabay, CY and Karaca, I and Kayıkçıoğlu, M and Keskin, M and Kılıç, T and Kırma, C and Kocabaş, U and Küçükoğlu, S and Mutlu, B and Nalbantgil, S and Okuyan, E and Okyay, K and Kaptan Özen, D and Özgül, S and Özpelit, E and Pirat, B and Sert, S and Sinan, ÜY and Şener, YZ and Tatlı, E and Tekkeşin, Aİ and Tutar, E and Ural, D and Yıldırımtürk, Ö},
title = {[Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)].},
journal = {Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir},
volume = {48},
number = {Suppl 1},
pages = {1-48},
doi = {10.5543/tkda.2020.97198},
pmid = {32250347},
issn = {1308-4488},
mesh = {*Betacoronavirus ; COVID-19 ; Cardiology/*standards ; Cardiovascular Diseases/epidemiology/*therapy/*virology ; Coronavirus Infections/*epidemiology ; Humans ; Pandemics ; Pneumonia, Viral/*epidemiology ; SARS-CoV-2 ; Societies, Medical ; Turkey ; },
abstract = {In December 2019, in the city of Wuhan, in the Hubei province of China, treatment-resistant cases of pneumonia emerged and spread rapidly for reasons unknown. A new strain of coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was identified and caused the first pandemic of the 21st century. The virus was officially detected in our country on March 11, 2020, and the number of cases increased rapidly; the virus was isolated in 670 patients within 10 days. The rapid increase in the number of patients has required our physicians to learn to protect both the public and themselves when treating patients with this highly infectious disease. The group most affected by the outbreak and with the highest mortality rate is elderly patients with known cardiovascular disease. Therefore, it is necessary for cardiology specialists to take an active role in combating the epidemic. The aim of this article is to make a brief assessment of current information regarding the management of cardiovascular patients affected by COVID-19 and to provide practical suggestions to cardiology specialists about problems and questions they have frequently encountered.},
}

*Betacoronavirus
COVID-19
Cardiology/*standards
Cardiovascular Diseases/epidemiology/*therapy/*virology
Coronavirus Infections/*epidemiology
Humans
Pandemics
Pneumonia, Viral/*epidemiology
SARS-CoV-2
Societies, Medical
Turkey

@article {pmid32170800,
year = {2020},
author = {Yan, Y and Chen, H and Chen, L and Cheng, B and Diao, P and Dong, L and Gao, X and Gu, H and He, L and Ji, C and Jin, H and Lai, W and Lei, T and Li, L and Li, L and Li, R and Liu, D and Liu, W and Lu, Q and Shi, Y and Song, J and Tao, J and Wang, B and Wang, G and Wu, Y and Xiang, L and Xie, J and Xu, J and Yao, Z and Zhang, F and Zhang, J and Zhong, S and Li, H and Li, H},
title = {Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019.},
journal = {Dermatologic therapy},
volume = {33},
number = {4},
pages = {e13310},
pmid = {32170800},
issn = {1529-8019},
mesh = {COVID-19 ; China ; Coronavirus Infections/*therapy ; Emollients/administration & dosage ; Gloves, Protective ; Hand Disinfection/methods ; *Health Personnel ; Humans ; Masks ; Mucous Membrane/*pathology ; Occupational Diseases/*prevention & control ; Pandemics ; Personal Protective Equipment ; Pneumonia, Viral/*therapy ; Skin/*pathology ; },
abstract = {Health professions preventing and controlling Coronavirus Disease 2019 are prone to skin and mucous membrane injury, which may cause acute and chronic dermatitis, secondary infection and aggravation of underlying skin diseases. This is a consensus of Chinese experts on protective measures and advice on hand-cleaning- and medical-glove-related hand protection, mask- and goggles-related face protection, UV-related protection, eye protection, nasal and oral mucosa protection, outer ear, and hair protection. It is necessary to strictly follow standards of wearing protective equipment and specification of sterilizing and cleaning. Insufficient and excessive protection will have adverse effects on the skin and mucous membrane barrier. At the same time, using moisturizing products is highly recommended to achieve better protection.},
}

COVID-19
China
Coronavirus Infections/*therapy
Emollients/administration & dosage
Gloves, Protective
Hand Disinfection/methods
*Health Personnel
Humans
Masks
Mucous Membrane/*pathology
Occupational Diseases/*prevention & control
Pandemics
Personal Protective Equipment
Pneumonia, Viral/*therapy
Skin/*pathology

@article {pmid41606213,
year = {2026},
author = {Ferreira, AGS and Garcia, HWC and da Silva, SS and da Silva, FAMF and Ferreira, JWL and da Silva Lopes, IMS},
title = {The role of sense of control and locus of control in depressive and anxious symptoms during COVID-19: an integrative review.},
journal = {Psicologia, reflexao e critica : revista semestral do Departamento de Psicologia da UFRGS},
volume = {39},
number = {1},
pages = {5},
pmid = {41606213},
issn = {0102-7972},
}

@article {pmid41605610,
year = {2026},
author = {Oreskovic, E and Petzold, A and Petropoulos, IN and Hau, S},
title = {Corneal confocal microscopy as a paraclinical test in neurodegenerative disease: a scoping review.},
journal = {The British journal of ophthalmology},
volume = {},
number = {},
pages = {},
doi = {10.1136/bjo-2025-328181},
pmid = {41605610},
issn = {1468-2079},
abstract = {Corneal confocal microscopy (CCM) is a non-invasive imaging technique that enables quantification of the corneal sub-basal nerve plexus and has emerged as a potential surrogate biomarker for peripheral neurodegeneration. This scoping review evaluated current evidence on the use of CCM in assessing corneal nerve fibre changes across neurodegenerative diseases (NDDs) and explored its potential as a paraclinical diagnostic and monitoring tool. A comprehensive search of PubMed and Scopus was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines to identify studies reporting quantitative CCM metrics, including corneal nerve fibre density (CNFD), corneal nerve branch density (CNBD) and corneal nerve fibre length (CNFL). Both cross-sectional and longitudinal studies of patients with NDDs were included, and findings were narratively synthesised. 50 studies were included: Parkinson's disease (n=13), multiple sclerosis (n=11), cerebrovascular accidents (n=7), post-COVID-19 neuropathy (n=5), amyotrophic lateral sclerosis (n=4), chronic inflammatory demyelinating polyneuropathy (n=4), Alzheimer's disease (n=3), Fabry disease (n=2) and neurofibromatosis type 1 (n=1). CNFL and CNFD were consistently reduced in Parkinson's disease, multiple sclerosis, cerebrovascular accidents, amyotrophic lateral sclerosis, chronic inflammatory demyelinating polyneuropathy and post-COVID-19 neuropathy, whereas CNBD results were inconsistent. The strongest evidence supported the role of CCM in Parkinson's disease and multiple sclerosis. CNFL and CNFD emerged as the most reliable CCM-derived metrics across NDDs, supporting their potential as objective biomarkers for neurodegeneration. While findings support the potential of CCM as a paraclinical diagnostic tool, methodological heterogeneity in image acquisition, analysis software and study design limited comparability. Standardised imaging and analysis protocols are needed to enable broader clinical application and validation across NDDs.},
}

@article {pmid41605119,
year = {2026},
author = {Groen, K and Hale, BG},
title = {Human autoantibodies against type I interferons in severe viral disease.},
journal = {Current opinion in virology},
volume = {74},
number = {},
pages = {101511},
doi = {10.1016/j.coviro.2026.101511},
pmid = {41605119},
issn = {1879-6265},
abstract = {Type I interferons (IFN-Is) are critical antiviral cytokines that restrict viral replication and limit viral disease. A remarkable recent discovery is that human autoantibodies (autoAbs) neutralizing the activities of IFN-Is phenocopy inborn errors of immunity and markedly exacerbate susceptibility to life-threatening infections. Development of these pathogenic autoAbs in humans is strongly linked to genetic and nongenetic factors affecting thymic function, and they are estimated to be present in >100 million people worldwide with a prevalence that increases with age. Here, we review major advances from the last few years that have improved our mechanistic understanding of human IFN-I autoAb development and function, as well as their association with a significant proportion of different severe viral diseases. In particular, we highlight how neutralizing IFN-I autoAbs can persist in individuals for decades, compromising IFN-I-mediated defenses, and underlying subsequent critical infections with diverse pathogens, including SARS-CoV-2, West Nile virus, tick-borne encephalitis virus, seasonal influenza viruses, herpesviruses, and rare zoonoses caused by MERS-CoV, flaviviruses, and avian H5N1 influenza A virus. Furthermore, we discuss how neutralizing IFN-I autoAbs facilitate severe adverse events with live-attenuated viral vaccines, such as the yellow fever or chikungunya virus vaccines, and suggest how implementation of IFN-I autoAb diagnostics in at-risk populations may be clinically beneficial with current prophylactic or therapeutic options. Finally, in the context of new experimental insights into how autoAbs block the ability of IFN-Is to engage with the IFNAR1/IFNAR2 receptors, we detail future opportunities to design advanced novel therapeutic strategies that might specifically mitigate IFN-I autoAb pathogenic effects.},
}

@article {pmid41605062,
year = {2026},
author = {Mattedi, FZ and Ribeiro, HS and Busatto, GF and Carvalho, CRR and Zanetta, DMT and Burdmann, EA and , },
title = {Acute respiratory distress syndrome and acute kidney injury in critically ill patients: A scoping review on this lung-kidney crosstalk.},
journal = {Journal of critical care},
volume = {93},
number = {},
pages = {155445},
doi = {10.1016/j.jcrc.2026.155445},
pmid = {41605062},
issn = {1557-8615},
abstract = {INTRODUCTION: The incidence of acute kidney injury (AKI) in patients with acute respiratory distress syndrome (ARDS) is high; nonetheless, the lung-kidney crosstalk remains unclear.

OBJECTIVE: Describe the association between ARDS and AKI in critically ill patients.

METHODS: This scoping review was conducted according to the JBI and PRISM-ScR and included studies that investigated critically ill patients with ARDS (Participants), described AKI-related outcomes (Concept), and were conducted in hospitals (Context). MEDLINE, Embase, and LILACS databases were searched for articles published up to January 2024. Only observational studies were considered. Data on the diagnosis of ARDS-AKI and other kidney-related outcomes were extracted.

RESULTS: A total of 2943 studies were screened, of which 28 were included in this review. Most studies were prospective and the majority originated from Europe. AKI was diagnosed using the KDIGO criteria in most studies and the pooled overall rate of AKI development across the studies was 46.8% (95% CI: 40.8-52.8). Two reports identified ARDS as an independent risk factor for AKI. Kidney replacement therapy was described in 17 studies. AKI recovery was described in only three studies. Seventeen studies evaluated hospital mortality, specifically in patients with ARDS-AKI, and found a greater mortality risk as compared to only ARDS.

CONCLUSIONS: This scoping review emphasizes the variability of the evidence, which hinders definitive conclusions about the association between ARDS and AKI, despite their common occurrence in critically ill patients. Therefore, a significant gap remains in our understanding of this lung-kidney interaction.},
}

@article {pmid41604899,
year = {2026},
author = {Saxena, SK and Yadav, J and Kishan, H and Harnam, AS and Kumar, S and Maurya, VK and Ansari, S and Paweska, JT and Ratho, RK},
title = {Pathogenesis and current advancement in treatment and prevention strategies for Human metapneumovirus.},
journal = {Virology},
volume = {617},
number = {},
pages = {110798},
doi = {10.1016/j.virol.2026.110798},
pmid = {41604899},
issn = {1096-0341},
abstract = {Human metapneumovirus (HMPV) is a well-identified paramyxovirus that has emerged as a significant global health threat, particularly following recent outbreaks in 2024-2025. It preferentially infects the respiratory epithelium and affects infants, the elderly, and immunocompromised populations. The clinical manifestations of the HMPV range from mild upper respiratory symptoms to severe diffuse bronchopneumonia. As of late 2024 and early 2025, HMPV has been responsible for 6.2% of positive respiratory illness tests and 5.4% of respiratory-associated hospitalizations in China, surpassing COVID-19, rhinovirus, and adenovirus. HMPV is a non-segmented, negative-sense single-stranded RNA virus with a genome of about 13.3 kb, and it is genetically related to Orthopneumovirus, particularly respiratory syncytial virus (RSV). Its transmission occurs primarily within households, and the virus poses significant risks to vulnerable populations. Immunologic responses to HMPV infections are diverse, with limited lasting immunity, leading to frequent reinfections. Diagnosis is problematic due to overlapping clinical manifestations of the disease alongside other respiratory viruses like RSV and influenza. Presently, no vaccines or antiviral treatments are available for HMPV, though several vaccine candidates are under investigation, including mRNA-1653 and IVX-A12, which have shown promising results in Phase I and Phase II clinical trials. Recent advances in understanding HMPV's molecular biology and immune modulation have led to exploring new therapeutic strategies, including monoclonal antibodies, fusion inhibitors, and RNA interference-based therapies.},
}

@article {pmid41604670,
year = {2026},
author = {Sun, M and Tang, F and Min, L and Wen, S and Wang, S and Jiang, H},
title = {Effects of Telehealth Interventions for People With Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials.},
journal = {JMIR mHealth and uHealth},
volume = {14},
number = {},
pages = {e70994},
doi = {10.2196/70994},
pmid = {41604670},
issn = {2291-5222},
mesh = {Humans ; *Parkinson Disease/therapy/psychology ; *Telemedicine/standards/statistics & numerical data ; Quality of Life/psychology ; Randomized Controlled Trials as Topic ; Activities of Daily Living/psychology ; COVID-19/epidemiology ; Depression ; },
abstract = {BACKGROUND: The global integration of telehealth into the management of Parkinson disease (PD) addresses critical gaps in health care access, especially for patients with limited mobility in underserved regions. Despite accelerated adoption during the COVID-19 pandemic, evidence regarding telehealth's multidimensional efficacy remains inconsistent. Previous meta-analyses reported conflicting outcomes for quality of life (QOL), motor symptoms, and neuropsychiatric comorbidities.

OBJECTIVE: This study aimed to quantitatively synthesize the effects of telehealth interventions across six core PD domains: (1) QOL, (2) depression, (3) anxiety, (4) motor symptoms, (5) activities of daily living (ADL), and (6) cognition.

METHODS: PubMed, Embase, Cochrane Library, Scopus, and Web of Science were systematically searched until June 21, 2024. In adherence to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, English-language randomized controlled trials evaluating telehealth interventions for PD were included. Study quality was assessed using the Cochrane Risk of Bias tool. A dual analytical approach using random-effects models was applied to address heterogeneity. Studies reporting a single effect size were analyzed using the Hartung-Knapp-Sidik-Jonkman correction. Studies with multiple dependent effect sizes were analyzed using a 3-level random-effects meta-analysis with t-distribution inference, accounting for sampling, within-study, and between-study variance. Effect sizes were expressed as standardized mean differences (SMD) with 95% CIs. Heterogeneity was quantified using the τ[2]; prediction intervals were not calculated due to the limited number of studies. Prespecified subgroup analyses examined intervention types (digital vs traditional telehealth) and follow-up durations. Sensitivity analyses and assessments for small-study effects (multilevel Egger tests, funnel plots) were conducted.

RESULTS: A total of 15 randomized controlled trials (765 participants) demonstrated significant telehealth benefits: QOL significantly improved on the Medical Outcomes Study 36-Item Short Form Health Survey and Brunnsviken Brief Quality of Life Scale (SMD 0.39, 95% CI 0.06-0.72; P=.03), with marginal improvement on the Parkinson Disease Questionnaire-8 (SMD -0.42, 95% CI -0.88 to 0.03; P=.07). Telephone-based interventions outperformed digital approaches (P=.002). Depression symptoms were significantly reduced (SMD -0.64, 95% CI -0.93 to 0.34; P<.001), particularly with traditional telehealth (P<.001). Anxiety also decreased significantly (SMD -0.64, 95% CI -0.92 to 0.35; P=.003) with negligible heterogeneity (I[2]=0%). Motor symptoms improved (SMD -0.46, 95% CI -0.69 to 0.24; P=.001), and ADL showed substantial impairment reduction (SMD -0.79, 95% CI -1.04 to -0.54; P=.002). Cognition was significantly enhanced (SMD 1.12, 95% CI 0.03 to 2.20; P=.045) though with moderate heterogeneity (I[2]=52.3%) and significant publication bias (P<.001). Follow-up duration did not significantly moderate effects.

CONCLUSIONS: Telehealth interventions significantly enhance multiple PD domains, with traditional (telephone/tablet-based) approaches demonstrating particular advantages for QOL and depression. Digital interventions showed more limited efficacy. These findings support telehealth as a multifaceted management tool for PD, although cognition outcomes require further investigation.

TRIAL REGISTRATION: PROSPERO CRD42024520169; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024520169.},
}

Humans
*Parkinson Disease/therapy/psychology
*Telemedicine/standards/statistics & numerical data
Quality of Life/psychology
Randomized Controlled Trials as Topic
Activities of Daily Living/psychology
COVID-19/epidemiology
Depression

@article {pmid41604358,
year = {2026},
author = {Palacio Varona, J and Rojas Manjarres, AM and Gómez-Buitrago, MI and Castro-Caro, J and Gonzalez-Parra, JD and Del Portillo, MC and Prada, A and Villegas-Gomez, GA},
title = {Global, regional and national patterns in ROP research up to the pre-COVID-19 era: A systematic bibliometric review between 1950 to 2020.},
journal = {European journal of ophthalmology},
volume = {},
number = {},
pages = {11206721261415977},
doi = {10.1177/11206721261415977},
pmid = {41604358},
issn = {1724-6016},
abstract = {Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness, predominantly affecting preterm infants. Global disparities in neonatal care and research capacity influence the volume and visibility of scientific production devoted to ROP across regions. This systematic bibliometric review aimed to characterize global, regional, and national patterns of ROP research published between 1950 and 2020, including temporal trends, geographic distribution, thematic focus, and citation impact. A systematic search of PubMed, Scopus, Web of Science, and SciELO identified 4,932 eligible articles. Most publications originated from the Region of the Americas (Pan American Health Organization, PAHO; 44.2%), the European Region (EURO; 28.0%), and the Western Pacific Region (WPRO; 16.0%). High-income countries accounted for 73.4% of the total output, whereas lower-middle- and low-income countries were markedly underrepresented. The most frequent research themes were risk/protective factors (25.0%) and treatment and outcomes (23.5%), while studies addressing surveillance and public health policies were scarce (6.3%). Scientific output increased markedly after the 1980s, with particularly rapid growth in recent decades in the Western Pacific and South-East Asia Regions. Citation analysis revealed substantial regional inequalities, with publications from high-income regions accounting for the majority of global citations and higher per-article impact. Overall, ROP research remains highly concentrated in high-income settings, reflecting persistent global disparities in scientific production and visibility. Strengthening research capacity and output in underrepresented regions is essential to promote more equitable evidence generation and to support informed decision-making in global eye health.},
}

@article {pmid41604346,
year = {2026},
author = {Cénat, JM and Darius, WP and Moshirian Farahi, SMM and Kibret, TC and Samson, E and Chen, R and Kuk, SW and Ogbuaku Jnr, K and Steacy, E and Labelle, PR and Madigan, S and Dalexis, RD},
title = {Prevalence and Correlates of Post-Traumatic Stress Disorder Symptoms During the COVID-19 Pandemic in Canada: A Systematic Review and Meta-analysis: Prévalence et corrélats des symptômes du trouble de stress post-traumatique pendant la pandémie de COVID-19 au Canada : Revue systématique et méta-analyse.},
journal = {Canadian journal of psychiatry. Revue canadienne de psychiatrie},
volume = {},
number = {},
pages = {7067437251408179},
doi = {10.1177/07067437251408179},
pmid = {41604346},
issn = {1497-0015},
abstract = {BackgroundInfectious disease outbreaks have been associated with significant psychological distress and trauma. In Canada, the COVID-19 pandemic's social disruptions have heightened mental health risks. While global studies report elevated posttraumatic stress disorder (PTSD) symptoms, Canadian findings remain limited and inconsistent. This meta-analysis estimated pooled prevalence of PTSD symptoms in Canada during the COVID-19 pandemic and examined potential moderators.MethodsA comprehensive search strategy was executed by research librarians across five databases (APA PsycInfo, CINAHL, Embase, MEDLINE and Web of Science) and on LitCovid. The PRISMA guidelines were used for data extraction and reporting. Random-effects meta-analyses were conducted to estimate pooled PTSD symptoms prevalence and explore potential moderators using the metaprop command in STATA/SE 19.5.ResultsThirty studies conducted between 2020 and 2022, with 52,565 participants aged 18 and older were included (65% weighted women). The pooled prevalence of PTSD symptoms was 22.2% (95% CI, 15.7% to 29.4%; I[2]=99.69). Prevalence was 32.1% in women, 26.1% in men (p = 0.399) and ranged from 16.1% in Quebec to 29.7% in Ontario (p = 0.091). Meta-regressions showed lower PTSD symptoms prevalence in Quebec (B=-0.16, p = 0.029). No significant differences in PTSD symptoms were found according to sex, healthcare worker status, assessment tool used, or data collection year.ConclusionsThis meta-analysis reveals a concerning prevalence of PTSD symptoms in the Canadian population during the COVID-19 pandemic. Contrary to expectations, no significant differences were found by sex or healthcare worker status, suggesting widespread psychological distress across the population. However, the substantial heterogeneity across studies limits the interpretation of these findings in the context of the COVID-19 pandemic. The results emphasize the need for inclusive and accessible mental health responses and further research on post-pandemic Canadians' mental health. Future studies should better disaggregate data by sex, age and race to address disparities and inform targeted public health policies and interventions.},
}

@article {pmid41603321,
year = {2026},
author = {Silveira, IB and Silva, GP and Sampaio, AVH and Tomé, MR and Chen, JE and de Jesus, AVS and Cançado, GGL},
title = {Synchronous Telemedicine Versus In-Person Care in Hepatitis C Treatment: A Systematic Review and Meta-Analysis.},
journal = {Journal of viral hepatitis},
volume = {33},
number = {3},
pages = {e70144},
doi = {10.1111/jvh.70144},
pmid = {41603321},
issn = {1365-2893},
mesh = {Humans ; *Telemedicine ; *Antiviral Agents/therapeutic use ; Sustained Virologic Response ; *Hepatitis C/drug therapy ; *Hepatitis C, Chronic/drug therapy ; COVID-19 ; Health Services Accessibility ; Treatment Outcome ; },
abstract = {Inequitable access to HCV treatment persists, particularly for rural and marginalised populations. Synchronous telemedicine (TM) could mitigate access barriers, but its comparative effectiveness versus in-person care is uncertain. We performed a systematic review and meta-analysis comparing synchronous TM with in-person care for HCV. The primary outcome was sustained virologic response (SVR); secondary outcomes were treatment initiation and completion. Subgroup analyses examined study design, therapy era (interferon vs. direct-acting antivirals [DAAs]), and setting (rural vs. non-rural). Narrative synthesis addressed people who use drugs (PWUD), incarcerated populations, pandemic-era cohorts, and economic evaluations. Fifteen studies involving 7.459 patients (2 RCTs, 13 observational) were included (13 meta-analysed). For SVR, the pooled effect showed no significant difference between interventions (odds ratio [OR] 1.60, 95% CI 0.69-3.68). Treatment initiation and completion were also not significantly different overall (initiation OR 7.59, 95% CI 0.79-72.81; completion OR 2.50, 95% CI 0.76-8.25), although exclusion of single influential studies yielded significant benefits for TM in sensitivity analyses. Subgroups suggested context-specific advantages: TM favoured SVR in rural settings (OR = 4.19, 95% CI 1.28-13.73) and in RCTs (OR = 10.42, 95% CI 7.41-14.67). Narrative evidence indicated that TM improved linkage and cure among PWUD and incarcerated individuals, preserved efficacy during COVID-19, and reduced costs. Overall, synchronous TM seems comparable to in-person care overall and may be superior in rural and marginalised populations.},
}

Humans
*Telemedicine
*Antiviral Agents/therapeutic use
Sustained Virologic Response
*Hepatitis C/drug therapy
*Hepatitis C, Chronic/drug therapy
COVID-19
Health Services Accessibility
Treatment Outcome

@article {pmid41602864,
year = {2025},
author = {Dasgupta, T and Russell, E and Carbajal, C and Horgan, G and Peterson, L and Mistry, HD and Buabeng, R and Wilson, M and Smith, V and Boulding, H and Sheen, KS and Van Citters, AD and Nelson, EC and Duncan, EL and von Dadelszen, P and , and Silverio, SA and Magee, LA},
title = {Seeking digital maternity healthcare during the pandemic health system shock: a systematic review of women's experiences in low- and middle-income countries.},
journal = {Frontiers in reproductive health},
volume = {7},
number = {},
pages = {1734456},
pmid = {41602864},
issn = {2673-3153},
abstract = {BACKGROUND: The pandemic created global disruption acting as a health system shock not seen before in living memory. As a consequence, there were significant implications for healthcare delivery in low- and middle-income countries. Challenges such as lockdown restrictions created substantial modifications to the delivery of maternity care. This review aims to explore the experiences of maternity care by women, specifically in low- and middle-income countries, during the pandemic global health system shock.

METHODS: A systematic search was conducted for qualitative literature published about maternity healthcare experiences during the pandemic. Studies which provided qualitative data on women's experiences of digital healthcare, and other maternity care reconfigurations in low- and middle-income countries were included. The studies underwent quality assessment using twelve criteria adapted from the quality appraisal tool developed by the Evidence for Policy & Practice Information (EPPI) Centre. Thematic synthesis was employed.

RESULTS: Of the 21,860 records identified, 30 met the inclusion criteria for this review. Across the 4 key predetermined areas of study: (1) Care seeking and experience; (2) Digital health; (3) Vaccination; and (4) Ethical future of maternity services; 10 concepts were reported upon, namely: (1.1) Emotional challenges and uncertainty, (1.2) Disruption of services, (1.3) Stigma and discrimination, and (1.4) Changing support systems; (2.1) Safety and reassurance, (2.2) Locus of responsibility; (3.1) Vaccine understanding and acceptance; and (4.1) Improvements for maternity care delivery, (4.2) Implementation of virtual care, (4.3) Education and empowerment.

CONCLUSION: Our findings suggest emotional challenges, isolation, and limited access to maternity services were prominent among pregnant individuals in low- and middle-income countries. This synthesis provides insights into how pandemic associated adaptations, which have been retained beyond, such as digital health solutions were experienced by women within constrained health systems, revealing both opportunities and persistent gaps in digital health access and equity. Although a review of low- and middle-income countries-there is learning to be taken from these settings which could easily be applied not only across low- and middle-income countries, but also in high-income settings, in the form of reverse (or "trickle-up") innovation to improve maternity care as we recover and re-build from the pandemic and offer more resilient ways of providing maternity care through future health system shocks. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42022355948, identifier CRD42022355948.},
}

@article {pmid41601020,
year = {2026},
author = {See, KC},
title = {Vaccination Against Respiratory Infections in Adults with Cancer: A Concise Guide for Clinicians.},
journal = {Vaccines},
volume = {14},
number = {1},
pages = {},
doi = {10.3390/vaccines14010105},
pmid = {41601020},
issn = {2076-393X},
abstract = {Global cancer incidence reached 20 million new cases across 185 countries in 2022, with approximately 10 million cancer-related deaths annually. Among adults with solid tumors and hematological malignancies, infections are a major contributor to morbidity and mortality, with respiratory infections playing a particularly significant role. These infections not only reduce life expectancy but can also delay cancer therapy, negatively affect treatment outcomes, and increase healthcare costs. In recent years, the burden of respiratory infections in this population has been driven by influenza virus, SARS-CoV-2, respiratory syncytial virus, Streptococcus pneumoniae, and Bordetella pertussis. Effective vaccines are available for all these pathogens and are recommended for adults with cancer, yet vaccination uptake remains suboptimal despite their heightened vulnerability. This review provides practical guidance for healthcare professionals on vaccinating adults with cancer against respiratory infections, summarizing key information to help clinicians address vaccination-related complacency, confidence, and convenience. Evidence from studies in both the general population and cancer patients consistently shows that vaccination benefits outweigh potential risks, with adverse event rates comparable to those seen in individuals without cancer. Early vaccination is encouraged, as there is limited justification for delaying immunization even when immune responses may be reduced. Vaccine dosing aligns with recommendations for the general population, with important exceptions. Live attenuated vaccines should be avoided because of the risk of replication and disease in immunocompromised patients, and selected groups may require booster doses to achieve adequate protection. Notably, cancer immunotherapy does not appear to impair vaccine-induced immune responses.},
}

@article {pmid41600988,
year = {2026},
author = {Alkhidir, M and Sridharan, K},
title = {Efficacy and Safety of mRNA-Based COVID-19 Vaccines in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.},
journal = {Vaccines},
volume = {14},
number = {1},
pages = {},
doi = {10.3390/vaccines14010072},
pmid = {41600988},
issn = {2076-393X},
abstract = {BACKGROUND: Solid organ transplant recipients (SOTRs) are highly vulnerable to severe COVID-19 infection, yet initial vaccine trials provided limited data on efficacy and safety in this immunocompromised population. Heterogeneous seroconversion rates and conflicting safety reports complicate the formulation of clear clinical guidelines. This systematic review and meta-analysis aim to aggregate existing evidence to determine the precise seroconversion and safety profiles of COVID-19 vaccines and identify key factors influencing immune response in SOTRs.

METHODS: A comprehensive literature search was conducted identifying 125 studies evaluating WHO/FDA-authorized vaccines in SOTRs. Outcomes were the pooled seroconversion proportion and safety profile. Subgroup analyses were performed based on vaccine type, transplanted organ, number of doses, and prior SARS-CoV-2 infection status, confirmed by leave-one-out sensitivity analysis and bootstrap methods.

RESULTS: Most studies assessed mRNA-based vaccines (123/125, 98.4%). The overall pooled seroconversion proportion across all SOTRs was significantly blunted at 0.49 (95% CI, 0.43 to 0.55), demonstrating high heterogeneity (I[2] = 94.2%). Seroconversion showed a clear positive dose-response relationship, increasing from 27% after one dose to 84% after four doses. Prior COVID-19 infection was the strongest predictor of a response, resulting in a pooled seroconversion of 0.90 (95% CI, 0.82 to 0.94; I[2] = 0%). Organ-specific analyses revealed the highest response in Liver recipients (0.80) and the lowest in Lung recipients (0.29). Vaccine platform analysis showed that the highest response was with mRNA-1273 (0.55) and the lowest with CoronaVac (0.29). The safety profile was limited.

CONCLUSIONS: SOTRs exhibit profound hypo responsiveness to COVID-19 vaccines; however, the extreme heterogeneity observed across studies necessitates a cautious interpretation of pooled seroconversion estimates. While the data indicates a significant dose-response relationship favoring an aggressive, multi-dose strategy, the apparent safety profile may reflect under-reporting and limited follow-up rather than confirmed safety equivalence. Rare but clinically critical outcomes, such as acute allograft rejection, remain inadequately characterized in the current literature. Consequently, while the prioritization of multi-dose regimens and hybrid immunity is supported to maximize protection, clinicians must recognize that individual responses remain highly variable, and the long-term immunological impact of repeated stimulation requires further standardized investigation.},
}

@article {pmid41600927,
year = {2025},
author = {Esposito, S and Aurelio, C and Cifaldi, M and Lazzara, A and Viafora, F and Principi, N},
title = {Prevention of Respiratory Infections in Children with Congenital Heart Disease: Current Evidence and Clinical Strategies.},
journal = {Vaccines},
volume = {14},
number = {1},
pages = {},
doi = {10.3390/vaccines14010011},
pmid = {41600927},
issn = {2076-393X},
abstract = {Background: Children with congenital heart disease (CHD) are at substantially increased risk for respiratory infections, which occur more frequently and with greater severity than in healthy peers. This heightened vulnerability stems from multifactorial immune impairment, including defects in innate and adaptive immunity, chronic inflammation related to abnormal hemodynamics and hypoxia, reduced thymic function, and genetic syndromes affecting both cardiac and immune development. Viral pathogens-particularly respiratory syncytial virus (RSV), influenza viruses, and SARS-CoV-2-account for most infections, although bacterial pathogens remain relevant, especially in postoperative settings. Methods: This narrative review summarizes current evidence on infection susceptibility in children with CHD, the epidemiology and clinical relevance of major respiratory pathogens, and the effectiveness of available preventive measures. Literature evaluating immunological mechanisms, infection burden, vaccine effectiveness, and passive immunization strategies was examined, along with existing national and international immunization guidelines. Results: Children with CHD consistently exhibit higher rates of hospitalization, intensive care unit admission, mechanical ventilation, and mortality following respiratory infections. RSV, influenza, and SARS-CoV-2 infections are particularly severe in this population, while bacterial infections, though less common, contribute substantially to postoperative morbidity. Preventive options-including routine childhood vaccines, pneumococcal and Haemophilus influenzae type b vaccines, influenza vaccines, COVID-19 mRNA vaccines, and RSV monoclonal antibodies-demonstrate strong protective effects. New long-acting RSV monoclonal antibodies and maternal vaccination markedly enhance prevention in early infancy. However, vaccine coverage remains insufficient due to parental hesitancy, provider uncertainty, delayed immunization, and limited CHD-specific evidence. Conclusions: Respiratory infections pose a significant and preventable health burden in children with CHD. Enhancing the use of both active and passive immunization is essential to reduce morbidity and mortality. Strengthening evidence-based guidelines, improving coordination between specialists and primary care providers, integrating immunization checks into routine CHD management, and providing clear, condition-specific counseling to families can substantially improve vaccine uptake and clinical outcomes in this vulnerable population.},
}

@article {pmid41600887,
year = {2026},
author = {Maslov, DE and Osipov, ID and Zabelina, DS and Pak, AA and Netesov, SV},
title = {Respiratory Syncytial Virus Prevalence and Genotypic Distribution in the Countries of the Former Soviet Union: A Systematic Review and Meta-Analysis.},
journal = {Viruses},
volume = {18},
number = {1},
pages = {},
doi = {10.3390/v18010126},
pmid = {41600887},
issn = {1999-4915},
support = {FSUS-2025-0017 and FSUS-2025-0012//Ministry of Science and Higher Education, Russian Federation/ ; The "Prioritet-2030" program//Novosibirsk State University/ ; },
mesh = {Humans ; *Respiratory Syncytial Virus Infections/epidemiology/virology ; *Respiratory Syncytial Virus, Human/genetics/classification ; Prevalence ; Genotype ; USSR/epidemiology ; Seasons ; COVID-19/epidemiology/virology ; Infant ; Child ; Child, Preschool ; Adult ; },
abstract = {Respiratory syncytial virus (RSV) is among leading global causes of lower respiratory tract infections, yet data from Russia and other states of the Former Soviet Union (FSU) remain fragmented and structurally inconsistent. This systematic review aims to map and synthesize existing evidence on RSV epidemiology and genotypic distribution across the FSU. Published studies from eLIBRARY and PubMed databases queried for RSV prevalence data, together with public health surveillance datasets, were used to summarize RSV prevalence research across eight FSU countries. Random-effects meta-analysis across age strata showed high prevalence in children before 6 (21%) and a progressive decline with age, which is in agreement with global data. Prevalence estimates showed a high degree of variability partially explained by study scope and clinical presentation. We observed COVID-19-related seasonal disruptions of RSV seasonality, followed by gradual post-pandemic stabilization. Genotypic data reflects global trends with two cosmopolitan clades, A.D and B.D, and their descendants, dominating in the region. The review is limited by uneven geographical and temporal coverage, and scarce data on adults. The review provides the first integrated summary of RSV epidemiology across the FSU and underscores the need for expanded regional surveillance and genomic reporting.},
}

Humans
*Respiratory Syncytial Virus Infections/epidemiology/virology
*Respiratory Syncytial Virus, Human/genetics/classification
Prevalence
Genotype
USSR/epidemiology
Seasons
COVID-19/epidemiology/virology
Infant
Child
Child, Preschool
Adult

@article {pmid41600815,
year = {2025},
author = {Hamza, IA and Mao, K and Gao, C and Hamza, H and Zhang, H},
title = {Elements of Viral Outbreak Preparedness: Lessons, Strategies, and Future Directions.},
journal = {Viruses},
volume = {18},
number = {1},
pages = {},
doi = {10.3390/v18010050},
pmid = {41600815},
issn = {1999-4915},
support = {FS-2024-34//CAS-ANSO/ ; 2023415//Chinese Academy of Sciences/ ; 24291703Z//Hebei Provincial Science and Technology Projects/ ; Qiankehe Platform Talents-GCC [2023] 046//Guizhou Provincial Science and Technology Projects/ ; },
mesh = {Humans ; *Disease Outbreaks/prevention & control ; *COVID-19/prevention & control/epidemiology/diagnosis ; Animals ; SARS-CoV-2 ; Pandemics/prevention & control ; *Virus Diseases/prevention & control/epidemiology/diagnosis ; Communicable Diseases, Emerging/prevention & control ; },
abstract = {Emerging and re-emerging viruses continue to pose major threats to public health. Their ability to adapt, cross species barriers, and spread rapidly can trigger severe outbreaks or even pandemics. Strengthening preparedness with comprehensive and efficient strategies is therefore essential. Here, we explore the key components of viral outbreak preparedness, including surveillance systems, diagnostic capacity, prevention and control measures, non-pharmaceutical interventions, antiviral therapeutics, and research and development. We emphasize the increasing importance of genomic surveillance, wastewater-based surveillance, real-time data sharing, and the One Health approach to better anticipate zoonotic spillovers. Current challenges and future directions are also discussed. Effective preparedness requires transparent risk communication and equitable access to diagnostics, vaccines, and therapeutics. The COVID-19 pandemic highlighted both the promise of next-generation vaccine platforms and the necessity of maintaining diagnostic capacity, as early testing delays hindered containment efforts. Countries adopted various non-pharmaceutical interventions: risk communication and social distancing proved to be the most effective, while combined workplace infection-prevention measures outperformed single strategies. These experiences highlight the importance of early detection, rapid response, and multisectoral collaboration in mitigating the impact of viral outbreaks. By applying best practices and lessons learned from recent events, global health systems can strengthen resilience and improve readiness for future viral threats.},
}

Humans
*Disease Outbreaks/prevention & control
*COVID-19/prevention & control/epidemiology/diagnosis
Animals
SARS-CoV-2
Pandemics/prevention & control
*Virus Diseases/prevention & control/epidemiology/diagnosis
Communicable Diseases, Emerging/prevention & control

@article {pmid41600776,
year = {2025},
author = {Giuliani, AAM and Chen, V and Law, N},
title = {Respiratory Viral Infection Prophylaxis and Treatment in the Transplant Population.},
journal = {Viruses},
volume = {18},
number = {1},
pages = {},
doi = {10.3390/v18010008},
pmid = {41600776},
issn = {1999-4915},
mesh = {Humans ; Antiviral Agents/therapeutic use ; *Respiratory Tract Infections/prevention & control/drug therapy/virology ; Respiratory Syncytial Virus Infections/prevention & control/drug therapy ; COVID-19/prevention & control ; Pre-Exposure Prophylaxis ; *Transplant Recipients ; Influenza, Human/prevention & control/drug therapy ; SARS-CoV-2 ; *Virus Diseases/prevention & control/drug therapy ; Viral Vaccines/immunology ; Post-Exposure Prophylaxis ; },
abstract = {Transplant patients experience high morbidity and mortality caused by respiratory viral infections (RVIs). In the past decade, numerous methods of prophylaxis and treatment have rapidly developed and continue to expand, with dozens of novel agents in preclinical and clinical trials. This includes recent scientific breakthroughs in virus structure, which have enabled the creation of respiratory syncytial virus (RSV) vaccines. While new vaccines, antivirals, monoclonal antibodies, and non-vaccine agents are becoming more available, their utility and safety in the transplant populations are often uncertain. This review summarizes the current landscape of RVIs in the transplant population, including approaches to pre- and post-exposure prophylaxis and treatment. We discuss the data behind vaccine timing, safety, and efficacy and current pre- and post-transplant recommendations, with a particular focus on influenza, SARS-CoV-2, and RSV. We also examine the potential benefits of antivirals, monoclonal antibodies, and novel agents used as prophylaxis, treatment, or adjuncts. While there remain many knowledge gaps, these new methods and ongoing advancements in RVI treatment and prevention promise to improve transplant patient outcomes.},
}

Humans
Antiviral Agents/therapeutic use
*Respiratory Tract Infections/prevention & control/drug therapy/virology
Respiratory Syncytial Virus Infections/prevention & control/drug therapy
COVID-19/prevention & control
Pre-Exposure Prophylaxis
*Transplant Recipients
Influenza, Human/prevention & control/drug therapy
SARS-CoV-2
*Virus Diseases/prevention & control/drug therapy
Viral Vaccines/immunology
Post-Exposure Prophylaxis

@article {pmid41600411,
year = {2026},
author = {Tiwari, AK and Gupta, MK and Mishra, SK and Meena, R and Patolsky, F and Narayan, RJ},
title = {Nanobiosensors: A Potential Tool to Decipher the Nexus Between SARS-CoV-2 Infection and Gut Dysbiosis.},
journal = {Sensors (Basel, Switzerland)},
volume = {26},
number = {2},
pages = {},
doi = {10.3390/s26020616},
pmid = {41600411},
issn = {1424-8220},
mesh = {*Dysbiosis/diagnosis/virology/microbiology ; Humans ; *COVID-19/diagnosis/virology/complications ; *Biosensing Techniques/methods ; *SARS-CoV-2/isolation & purification/pathogenicity ; *Gastrointestinal Microbiome ; *Nanotechnology/methods ; },
abstract = {The emergence of SARS-CoV-2 posed a great global threat and emphasized the urgent need for diagnostic tools that are rapid, reliable, sensitive and capable of real-time monitoring of SARS-CoV-2 infections. Recent investigations have identified a potential connection between SARS-CoV-2 infection and gut dysbiosis, highlighting the sophisticated interplay between the virus and the host microbiome. This review article discusses the eminence of nanobiosensors, as state-of-the-art tools, to investigate and clarify the connection between SARS-CoV-2 pathogenesis and gut microbiome imbalance. Nanobiosensors are uniquely advantageous owing to their sensitivity, selectivity, specificity, and reliable monitoring capabilities, making them well-suited for identifying both viral particles and microbial markers in biological samples. We explored a range of nanobiosensor platforms and their potential use for concurrently monitoring the gut dysbiosis induced by different pathological conditions. Additionally, we explore how advanced sensing technologies can shed light on the mechanisms driving virus-induced dysbiosis, and the implications for disease progression and patient outcomes. The integration of nanobiosensors with microfluidic devices and artificial intelligence algorithms has also been explored, highlighting the potential of developing point-of-care diagnostic tools that provide comprehensive insights into both viral infection and gut health. Utilizing nanotechnology, scientists and healthcare professionals may gain a more profound insight into the complex interaction dynamics between SARS-CoV-2 infection and the gut microenvironment. This could pave the way for enhanced diagnostic and prognostic approaches, treatment courses, and patient care for COVID-19.},
}

*Dysbiosis/diagnosis/virology/microbiology
Humans
*COVID-19/diagnosis/virology/complications
*Biosensing Techniques/methods
*SARS-CoV-2/isolation & purification/pathogenicity
*Gastrointestinal Microbiome
*Nanotechnology/methods

@article {pmid41599373,
year = {2026},
author = {Wan, X and Cui, X and Liang, K and Huang, J and Chen, K and Chen, W and Song, G},
title = {The Emerging Promise of Pentacyclic Triterpenoid Derivatives as Novel Antiviral Agents Against SARS-CoV-2 Variants.},
journal = {Molecules (Basel, Switzerland)},
volume = {31},
number = {2},
pages = {},
doi = {10.3390/molecules31020325},
pmid = {41599373},
issn = {1420-3049},
support = {2025A1515010495//Guangdong Basic and Applied Basic Research Foundation/ ; 2024KQNCX197//Youth Innovative Talents Project from the Department of Education of Guangdong Province/ ; },
mesh = {*Antiviral Agents/pharmacology/chemistry/therapeutic use ; *SARS-CoV-2/drug effects ; Humans ; *Pentacyclic Triterpenes/pharmacology/chemistry/therapeutic use ; *COVID-19 Drug Treatment ; Structure-Activity Relationship ; COVID-19/virology ; *Triterpenes/chemistry/pharmacology ; Spike Glycoprotein, Coronavirus/metabolism ; },
abstract = {The continuous emergence of SARS-CoV-2 variants, especially the Omicron strain with its heightened transmissibility, has posed ongoing challenges to the efficacy of existing vaccine and drug regimens. This situation highlights the pressing demand for antiviral drugs employing novel mechanisms of action. Pentacyclic triterpenoids (PTs), a structurally varied group of compounds derived from plants, exhibit both antiviral and anti-inflammatory activities, making them attractive candidates for further therapeutic development. These natural products, along with their saponin derivatives, show broad-spectrum inhibitory effects against multiple SARS-CoV-2 variants (from Alpha to Omicron) via interactions with multiple targets, such as the spike protein, main protease (Mpro), RNA-dependent RNA polymerase (RdRp), and inflammatory signaling pathways. This review consolidates recent findings on PTs and their saponins, emphasizing their influence on the key structural features required for inhibiting viral attachment, membrane fusion, reverse transcription, and protease function. We systematically summarized the structure-activity relationships and their antiviral results of PTs based on different target proteins in existing studies. Furthermore, this work points toward new strategies for designing multi-target PT-based inhibitors with improved efficacy against Omicron and future variants.},
}

*Antiviral Agents/pharmacology/chemistry/therapeutic use
*SARS-CoV-2/drug effects
Humans
*Pentacyclic Triterpenes/pharmacology/chemistry/therapeutic use
*COVID-19 Drug Treatment
Structure-Activity Relationship
COVID-19/virology
*Triterpenes/chemistry/pharmacology
Spike Glycoprotein, Coronavirus/metabolism

@article {pmid41599072,
year = {2026},
author = {Dave, RS and Fox, HS},
title = {Synergy of SARS-CoV-2 and HIV-1 Infections in the Human Brain.},
journal = {Pathogens (Basel, Switzerland)},
volume = {15},
number = {1},
pages = {},
doi = {10.3390/pathogens15010089},
pmid = {41599072},
issn = {2076-0817},
mesh = {Humans ; *COVID-19/virology/pathology/complications/epidemiology ; *HIV Infections/virology/pathology/complications ; *SARS-CoV-2 ; *HIV-1 ; *Brain/virology/pathology ; Microglia/virology/pathology ; Coinfection/virology ; Cytokines/metabolism ; },
abstract = {This review explores the interplay between SARS-CoV-2 and HIV-1 infections within the human brain, highlighting the significant neurological implications of these viral infections. SARS-CoV-2 can infect the central nervous system (CNS), with evidence of the virus detected in various brain regions, including the hypothalamus, cerebellum, and olfactory bulb. This infection is linked to microglial activation and neuroinflammation, which can lead to severe neurological outcomes in affected individuals. Autopsy studies revealed microglial changes, including downregulation of the P2RY12 receptor, indicating a shift from homeostatic to inflammatory phenotype. Similar changes in microglia are found in the brains of people with HIV-1 (PWH). In SARS-CoV-2, the correlation between inflammatory cytokines, such as IL-1, IL-6, and MCP-1, found in cerebrospinal fluid and brain tissues, indicates significant neurovascular inflammation. Astrogliosis and microglial nodules were observed, further emphasizing the inflammatory response triggered by the viral infections, again in parallel to those found in the brains of PWH. Epidemiologic data indicate that although SARS-CoV-2 infection rates in PWH mirror those in People without HIV (PWoH) populations, Long-COVID prevalence is markedly higher among PWH. Evidence of overlapping cognitive impairment, mental health burden, and persistent neuroinflammation highlights diagnostic complexity and therapeutic gaps. Despite plausible mechanistic synergy, direct neuropathological confirmation remains scarce, warranting longitudinal, biomarker-driven studies. Understanding these interactions is critical for developing targeted interventions to mitigate CNS injury and improve outcomes.},
}

Humans
*COVID-19/virology/pathology/complications/epidemiology
*HIV Infections/virology/pathology/complications
*SARS-CoV-2
*HIV-1
*Brain/virology/pathology
Microglia/virology/pathology
Coinfection/virology
Cytokines/metabolism